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THE ROLE OF ADENOSINE SIGNALING IN MATURE ERYTHROCYTES AND 
ERYTHROID PROGENITORS 
 
Hong Liu 
 
Advisory Professor: Yang Xia, M.D., Ph.D. 
        Adenosine is a ubiquitous nucleoside in almost all the cells throughout our 
bodies. It is highly induced particularly under hypoxia or energy depletion 
conditions. Adenosine functions as a critical ligand, after binding to membrane-
associated adenosine receptors, adenosine initiates a downstream signaling 
cascade and subsequently contributes to functions of nervous system, immune 
response, vascular function and even metabolism.  
        Hypoxia is a condition with limited O2 availability in the whole body or a region 
of the body. It is a major consequence of many respiratory and cardiovascular 
diseases, as well as for people living and working at high altitudes or other low O2 
conditions. Without intervention, it can progress to pulmonary and cerebral edema, 
stroke, cardiovascular dysfunction and death. Although hypoxia-induced tissue 
damage is a serious condition with high morbidity and mortality, safe and effective 
mechanism-based therapies are limited.  
        The erythrocyte is the most abundant circulating cell type and functions as the 
only cell-type responsible for O2 availability in peripheral tissues. Its fundamental 
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function, O2 release capacity and O2 delivery capacity, is determined by 
hemoglobin-O2 binding affinity and cell number, respectively. 
        Although adenosine signaling is beneficial under stress conditions in various 
organs and tissues via activation of different adenosine receptors, its significance 
and functional role in the erythroid lineage, particularly under stress conditions, are 
still unclear. 
        My dissertation employing multi-disciplinary approaches including human 
studies, novel genetic tools, and sophisticated pharmacological studies coupled 
with metabolomic profiling shows for the first time that 1) CD73-dependent 
elevation of plasma adenosine signaling via erythrocyte specific ADORA2B 
coupled with AMP-activated protein kinase is a key mechanism for hypoxia 
adaptation via induction of 2,3-BPG production with O2 release to counteract 
severe hypoxia. 2) Adenosine signaling via erythroid ADORA2B is a previously 
unrecognized purinergic signaling responsible for stress erythropoiesis by 
regulation of erythroid commitment in a hypoxia-inducible factor 1-alpha dependent 
manner.  
        Thus, my research has identified that adenosine signaling functions as a novel 
molecular mechanism involved in the regulation of erythrocyte O2 release capacity 
and O2 delivery capacity, providing therapeutic possibilities to enhance O2 
availability and prevent stress-induced tissue damage and inflammation, a strong 
foundation for future clinical trials to treat diseases associated with hypoxia or 
hematology disorders provided by my doctoral work. 
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1.1 Background of adenosine signaling 
1.1.1 Metabolism of adenosine 
        Adenosine is ubiquitously produced in almost all of the cells in our bodies under 
physiological condition and further produced under hypoxia or energy depletion 
condition. As a building block and a critical intermediate metabolite of nucleic acids, 
adenosine is a key signaling molecule that orchestrates the cellular response to 
hypoxia, energy depletion and tissue damage by activation of its G-protein coupled 
receptors (GPCR) on multiple cell types1. Under normal physiological conditions, both 
extracellular and intracellular adenosine levels are in the nanomolar range. However, 
under stress conditions, ATP is released from injured cells such as endothelial cells2 
and neutrophils3 via transmembrane protein channel including pannexins4 or 
connexins3, 4, and subsequently dephosphorylated to extracellular adenosine by ecto-
nucleotidases including CD39, which converts ATP to ADP/AMP and CD73, which 
converts AMP to adenosine5, 6. Under pathological conditions, extracellular adenosine 
concentrations can reach the millimolar range7. Generation of extracellular adenosine 
through these pathways is the major source of extracellular adenosine production 
under hypoxia-induced injury. In addition, extracellular adenosine is regulated by 
adenosine deaminase (ADA), which is responsible for the degradation of extracellular 
adenosine into inosine8. Moreover, extracellular adenosine signaling is terminated by 
equilibrative nucleoside transporters (ENTs), which are involved in the cellular uptake 
of adenosine. Once inside the cell, adenosine is metabolized by two enzymes, 
adenosine kinase (ADK) and adenosine deaminase (ADA). ADA catalyzes the 
irreversible conversion of adenosine to inosine. ADK phosphorylates adenosine to 
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AMP, and is critical for regulating intracellular levels of adenosine and maintaining 
intracellular levels of adenine nucleotides7. Intracellular adenosine homeostasis is also 
maintained by bi-directional equilibrative nucleoside transporters (ENTs) on the plasma 
membrane, through facilitated diffusion of adenosine in the direction of the 
concentration gradient (Figure 1)9. 
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Figure. 1. Metabolism of adenosine signaling.  
Cells release ATP through connexins or pannexins channels under hypoxia and other 
stress conditions. The accumulation of extracellular ATP is dephosphorylated to 
adenosine (A) by 2 ecto-nucleotidases including CD39 and CD73. Adenosine can 
further be metabolized by adenosine deaminase (ADA) to inosine or functions as a 
signaling molecule by activation of its adenosine receptors (AR) on multiple cell types. 
Once uptake by equilibrative nucleoside transporters (ENTs), adenosine is further 
metabolized by adenosine kinase (ADK) to AMP, adenosine deaminase (ADA) to 
inosine, or S-adenosylhomocytesine hydrolase (SAHH) to adenosylhomocysteine 
(AdoHcy).  
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1.1.2. Adenosine signaling via adenosine receptors 
        Increases in extracellular adenosine in turn elicit various responses on target cells 
by engaging cell surface adenosine receptors both in physiological and pathological 
conditions10. As GPCRs, adenosine receptors all have a single polypeptide chain which 
is a structural motif forming seven transmembrane helices. There are four adenosine 
receptors (ADORA1, ADORA2A, ADORA2B, and ADORA3), and each receptor has a 
cellular or tissue specific distribution and distinct affinity for adenosine11.  ADORA1, 
ADORA2A, and ADORA3 have a high affinity to extracellular adenosine, while 
ADORA2B has the lowest affinity to extracellular adenosine. Thus, ADORA2B is 
normally activated under pathological conditions due to excess accumulation of 
extracellular adenosine. A1 and A3 adenosine receptors are coupled to adenylyl 
cyclase by the inhibitory G-protein subunit (Gαi) and thereby can lower intracellular 
levels of the second messenger cyclic adenosine monophosphate (cAMP). In contrast, 
the A2A and A2B adenosine receptors are commonly coupled to adenylyl cyclase by 
the stimulatory G-protein subunit (Gαs) and therefore can induce intracellular cAMP 
levels. Therefore, signaling through adenosine receptors plays important roles in the 
regulation of intracellular cAMP and thereby regulate multiple cellular functions 
including vasodilation in endothelial cells, neurotransmitter release from neuronal cells, 
neutrophil chemotaxis and vascular smooth muscle cell relaxation12, 13 (Figure 2).  In 
addition, other signaling molecules including phospholipase C (PLC), calcium, nitric 
oxide (NO), reactive oxygen species (ROS), PI3K-AKT, extracellular signal-protein 
kinase (ERK), and mitogen-activated protein kinases (MAPKs) are implicated 
functioning downstream of adenosine receptors and subsequently regulating multiple 
cellular functions. For example, activation of ADORA2A stimulates the PLC pathway 
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and adenylate cyclase pathway14. ADORA2A signaling is also engaged in modulation 
of neutrophil function by regulating production of ROS15, 16. By modulation of NO 
production via vascular endothelial cells, adenosine through ADORA2A receptor 
functions as a potent vasodilator involved in tissue blood flow and cellular 
homeostasis17, 18. In addition, shear stress-mediated elevated adenosine activates 
ADORA2B, subsequently contributes to endothelial NO synthase phosphorylation via 
PI3K-AKT, and further generates NO19. Both pharmacological and genetic studies 
show that adenosine ADORA2B induces inflammatory cytokine IL-6, and contributes 
to the renal fibrosis20. The activation of ADORA3 triggers MAPK, and contributes to the 
critical role of cell growth, survival and differentiation21. Other studies report that 
activation of ADORA3 modulates the proliferation of melanoma cells by regulation of 
ERK pathway (Figure 2)22.  Thus, activation of adenosine receptors are involved in 
multiple cellular function via multiple downstream signaling cascade.  
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Figure. 2. Adenosine receptor-mediated signaling pathways. Extracellular 
adenosine functions as signaling molecule by engaging cell surface adenosine 
receptors (ADORA1, ADORA2A, ADORA2B, and ADORA3). ADORA1 and ADORA3 
adenosine receptors are coupled to adenylyl cyclase (AC) by the inhibitory G-protein 
subunit (G i) and thereby can lower intracellular levels of the second messenger cyclic 
adenosine monophosphate (cAMP). In contrast, the ADORA2A and ADORA2B 
adenosine receptors can induce AC by the stimulatory G-protein subunit (G s) and 
therefore can induce intracellular cAMP levels. Activation of both ADORA1 and 
ADORA2B stimulates phosphatidylinositol 3-kinase (PI3K)/AKT pathway, and 
activation of both ADORA2A and ADORA2B induces release of ROS, EETs, and PGI 
2 . PKA, protein kinase A; PLC, phospholipase C; ROS, reactive oxygen species; EETs, 
epoxyeicosatrienoic acids; PGI 2, prostacyclin; eNOS, endothelial NO synthase; NO, 
nitric oxide; IL-6, interleukin 6; MAPK, mitogen-activated protein kinases; ERK, 
extracellular signal-protein kinase. 
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1.1.3. Adenosine signaling in physiological and pathological conditions 
        Adenosine is involved in numerous critical physiological processes via activation 
of its adenosine receptors including modulation of nervous system, immune response, 
vascular function and metabolism13, 23. Adenosine-mediated biological function is 
mainly dependent on activation of adenosine receptors, and responses of these cell 
surface receptors are predominantly determined by adenosine concentrations. Since 
function of adenosine signaling is through activation of A1, A2A or A3 adenosine 
receptors, w . In contrast, activation 
of ADOAR2B requires a higher adenosine concentrations which generally exist under 
pathophysiological conditions24. With the development and generation of various 
adenosine receptors agonists or antagonists and four adenosine receptor knockout 
mouse models, adenosine signaling has been demonstrated as an essential player 
under pathophysiological conditions by modulation of inflammation, ischemic tissue 
injury, fibrosis and tissue remodeling25-27.  
1. 2.  Beneficial role of adenosine signaling during acute stage 
        Recent studies indicate that extracellular adenosine functions as a signaling 
molecule, which plays an essential role in adaptation to stress especially hypoxia26, 28, 
29. Extracellular adenosine is induced during limited oxygen availability or acute injury, 
and adenosine is critical for hypoxia adaptation, maintenance of cellular function and 
protection of hypoxia-induced tissue injury. Under acute hypoxic conditions, adenosine 
plays various beneficial role including vasodilatory effect, anti-vascular endothelial 
leakage and anti-inflammatory response30-34. 
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1.2.1. Beneficial role in acute heart injury 
        Beneficial role of adenosine in acute stage was initially found in cardiovascular 
system showing that adenosine functions as a potent vasodilator increasing blood flow 
to coronary arteries 35. Later on, adenosine was implicated to play a generally protective 
role in the heart by regulation of heart rate, coronary flow, contraction, inflammatory 
control and tissue remodeling36. All four adenosine receptors are known to be involved 
in coronary flow. Generally, adenosine exerts its cardiac electrophysiologic effects 
mainly through the activation of ADORA1 that leads to a reduction in contraction rate37. 
Adenosine A2A receptor is the major receptor subtype responsible for coronary blood 
flow regulation in endothelial-dependent and -independent manner38, previous study 
reported that adenosine increase coronary flow via vasodilation by promotion of 
prostacyclin release39. Regadenoson (Lexiscan), a specific ADORA2A agonist, was 
approved by FDA and utilized for diagnosis of myocardial perfusion imaging40. In 
addition, the Eltzschig group reported that CD73-mediated adenosine signaling via the 
ADORA2B is important in cardioprotection by ischemic preconditioning. However, 
Chen and colleagues reported that selective inhibition of adenosine A3 receptor 
significantly attenuate pressure overload-induced left ventricular hypertrophy and 
dysfunction41. These results suggest that selective CD73 agonists and ADORA2B 
agonists are potential therapeutic possibilities for myocardial ischemia, and specific 
ADORA3 antagonists may be a novel strategy to counteract pressure overload-induced 
left ventricular hypertrophy and dysfunction41, 42.  
 
1.2.2. Beneficial role in acute lung injury 
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        Acute lung injury (ALI) is defined as pulmonary edema and severe hypoxia. 
Multiple factors including pneumonia, aspiration or lung contusion, or indirect injury 
such as sepsis, severe trauma, blood transfusion cause ALI. Approximately 200,000 
patients develop ALI in the US annually. However, due to the lack of understanding the 
molecular mechanism involved in the development and progression of ALI, no effective 
therapeutic options are available. Several groups reported that adenosine serves 
beneficial functions on features of ALI such as enhancing alveolar-capillary barrier 
function and dampening inflammation, and substantially protects against ALI resulting 
from hypoxia or ischemia43, 44. Follow-up genetic and pharmacological studies reported 
that the adenosine mediated beneficial role in ALI is via ADORA2B in a CD73 
dependent manner45, 46. Therefore, these studies provide potential development of 
adenosine-based therapies for the treatment of ALI44, 47, 48. 
1.2.3. Beneficial role in acute kidney injury 
        Acute kidney injury (AKI), characterized as the rapid dysfunction of kidney, is 
currently the leading cause of mortality and morbidity in hospitalized patients, therefore 
effective therapeutic strategies are urgently needed. Among multiple factors, renal 
ischemia is the most common cause of AKI. Previous studies indicated that all four 
adenosine receptors are expressed in the kidney and are involved in progression of 
AKI49. Particularly, several studies reported adenosine A1 receptor signaling protects 
the kidney from ischemia-reperfusion injury50-53.  Linder’s group showed that adenosine 
A2A receptor signaling prevents ischemia-induced injury via modulation of 
inflammatory cells54, 55. In addition, pharmacological and genetic studies demonstrate 
that adenosine A2B receptor signaling is involved in renal protection during 
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preconditioning56. In contrast, activation of the ADORA3 is implicated as detrimental 
during renal ischemia52. 
1.2.4. Beneficial role in brain 
        As an important signaling molecule, adenosine coupling with its specific receptor 
functions as an upstream neuromodulator of neurotransmitters involved in the 
homeostasis and modulation of multiple brain function57, 58.  For example, previous 
studies demonstrated that adenosine is present in the extracellular fluid in brain, its 
level is dramatically induced in the condition of hypoxia or ischemia, and subsequently 
plays critical effects through activation of its specific receptors. Although all four 
adenosine receptors are expressed in the mouse forebrain, ADORA1 and ADORA2A 
have the highest abundance in the brain.  Thus, those two adenosine receptors play 
critical roles in the brain function, while ADORA2B and ADORA3 have relatively modest 
impact on brain function59, 60. It is found that ADORA1 is located presynaptically, 
postsynaptically and nonsynaptically in brain59, and mainly underlies effect of 
adenosine in neuronal circuits by selectively depressing excitatory synaptic 
transmission61. Both pharmacological evidence and genetic ADORA1 knockout mouse 
studies demonstrate neuro-protective role of ADORA1 in ischemia/hypoxia models of 
brain injury62. In contrast, ADORA2A are demonstrated to have a widespread 
distribution in the brain59. Several lines of evidence suggest that adenosine signaling 
via ADORA2A is neuroprotective under different pathological conditions including 
hypoxia63, ischemia64, 65, and hypoglycemia66. Mechanistic studies demonstrated 
adenosine-mediated protective effect in the brain is through ADORA2A by controlling 
brain vascular function through endothelial cells. For instance, ADORA2A plays a 
beneficial role in preventing brain ischemia by induction of cerebral blood flow (CBF) in 
12 
 
 
 
 
multiple conditions  including energy failure, tissue acidosis, imbalance of ion 
homeostasis and cytotoxic edema67, 68. In addition, Winn and colleagues found that the 
capacity to modulate CBF in response to hypotension was significantly impaired in 
ADORA2A knockout mice, and treatment with extracellular adenosine transporter 
inhibitor, dipyridamole, significantly increases circulating adenosine concentrations and 
subsequently improves CBF in mice, indicating the importance of adenosine 
ADORA2A in physiologic vascular regulation of  CBF69. Furthermore, both 
pharmacological and genetic studies demonstrated that ADORA2A stimulates 
proliferation of Schwann cells70. Additional studies showed that specific activation of 
other adenosine receptors contributes to the adenosine-mediated neuroprotective 
effects as well. For instance, preclinical study showed that A3 specific agonist prevents 
ischemic brain injury through suppression of  apoptosis in wild type mice, but not in the 
ADORA3-deficient mice71. Clinical human studies demonstrated that adenosine plays 
a role of vasodilatation in the cerebral circulation which can be applied for investigation 
of cerebrovascular perfusion capacity in patients with carotid occlusive disease72.  
Overall, adenosine singling via its specific receptors plays an important role in brain 
function and modulating adenosine signaling is likely an effective treatment for brain 
ischemic injury and damage. 2.5.  
1.2.5 Beneficial role in multiple organ damage at acute stage 
        Adenosine was reported to be beneficial under stress conditions in various organs 
and tissues through different adenosine receptors 73-76. Several studies report that 
adenosine play a otoprotective role in the auditory system to counteract intense noise 
exposure 77, 78. Cronstein’s group demonstrate that adenosine A2A signaling plays 
beneficial role in skin by promoting would healing and angiogenesis 76. Colgan and 
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colleagues used pharmacologic and genetic approaches to show that adenosine 
signaling via the A2B receptor attenuates tissue injury and inflammation in mucosal 
organs during intestinal ischemia and colitis79-82. Gnad et al. demonstrate that 
adenosine stimulate brown adipose tissue thermogenesis via ADORA2A, and 
ADORA2A selective agonist prevent high fat diet-induced obesity in mice 83. Linden’s 
group reported that elevated adenosine protects the liver from ischemic reperfusion 
injury via ADORA2A signaling 84. In addition, they show that ADORA2A signaling 
prevents pulmonary inflammation in a sickle cell disease (SCD) mouse model by 
reducing invariant natural killer cells. Therefore, FDA-approved ADOA2A specific 
agonist, regadenoson, is currently utilized to conduct a clinical trial in the treatment of 
patients with SCD 85, 86. 
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Table 1. The beneficial role of adenosine signaling in acute conditions 
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1.3 Adenosine signaling in erythrocyte 
        Although erythrocyte is the most abundant cell type in the body, the role of 
adenosine in erythrocyte has not been recognized. Recently, our laboratory first 
reported the functional role of adenosine signaling in erythrocyte in physiology condition. 
Erythrocyte is the major source of O2 to each organ and tissue, and its O2 carrying 
capacity is mainly regulated by hemoglobin- binding O2 affinity. Previous studies 
showed that hemoglobin- binding O2 affinity is tightly regulated by the 2,3-
bisphosphoglycerate (2,3-BPG), which is an important erythroid specific metabolite 
existing in the glycolytic pathway. However, how the level of 2,3-BPG was regulated is 
still unclear. By using genetic mouse models, pharmacological tools coupled with 
human evident, we revealed an important role of adenosine signaling in the regulation 
of erythrocyte 2,3-BPG. In details, we showed that adenosine specific analogue, 5’-N-
ethylcarboxamidoadenosine (NECA), can directly induces 2,3-BPG levels in cultured 
mouse mature RBCs. Furthermore, by using four adenosine receptor deficient mice 
models, we showed that NECA can induce 2,3-BPG level in cultured RBCs isolated 
from WT, Adora1, Adora2a and Adora3 mice, but not in the Adora2b mice, which 
indicates that adenosine signaling-induced erythrocyte 2,3-BPG in RBC is via 
ADORA2B. However, what is the significance and functional role of adenosine 
signaling-mediated regulation of RBC 2,3-BPG particularly in stress condition, and how 
2,3-BPG was regulated by adenosine ADORA2B in RBC is still unclear. These 
important questions will be further addressed in the Chapter 2 of my dissertation. 
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1.4 High altitude hypoxia 
        High altitude hypoxia is a condition in which the O2 availability is limited, 
therefore O2 delivery from circulation to peripheral tissues is limited. This directly 
causes poor exercise performance, even poor walking performance, and it can 
have substantial impact on overall well-being and cognitive function. Without 
intervention, high altitude hypoxia induces pulmonary edema, vascular damage 
and interstitial fibrosis and death. Thus, improving O2 delivery at the tissue level 
has the potential to improve peripheral oxygen delivery and thereby raise exercise 
performance and reverse cognitive deficits caused by hypoxemia. While the 
relevance of improving O2 delivery has clear impact on military veterans with 
hypoxemia secondary to chronic respiratory diseases, high altitude residence can 
cause similar levels of hypoxemia. Current strategies to counteract hypoxia are 
limited due to a lack of fundamental understanding of the molecular mechanisms 
underlying adaptation to hypoxia.  The erythrocyte is the most abundant cell type 
in the circulation and is responsible for delivery of O2 to peripheral tissues. To 
function effectively in O2 uptake, transport and delivery, erythrocytes tightly 
dependent on sophisticated regulation of Hb-O2 affinity by endogenous allosteric 
modulators. One of the best known allosteric modulators is (2,3-BPG), a metabolic 
byproduct of glycolysis synthesized primarily in erythrocytes for the purpose of 
regulating Hb-O2 affinity87. It has been known for more than four decades that when 
humans ascend to high altitude the concentration of 2,3-BPG in erythrocytes 
increases significantly and its elevation is correlated with an increased capacity of 
O2 release from hemoglobin88. However, the molecular basis underlying altitude 
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hypoxia mediated induction of erythrocyte 2,3-BPG  remains unknown and the 
functional role of elevated erythrocyte 2,3-BPG in high altitude adaptation is 
unclear.   
1.5 Erythropoiesis and stress erythropoiesis  
        Erythropoiesis is an dynamic process to synthesize new erythrocyte, the only 
cell-type responsible for delivering O2 to peripheral tissues in our body. Basically, 
it can be divided into two types of erythropoiesis including primitive erythropoiesis 
and definitive erythropoiesis. Primitive erythropoiesis is occurred in the fetal life, 
which included 3 stages based on the duration of pregnancy. The first 2 months 
called mesoblastic stage which was occurred in yolk sac. The second stage-
hepatic stage-was mainly happened in liver, spleen and lymphoid organs. The last 
stage-myeloid stage-was occurred in red bone marrow. Definitive erythropoiesis is 
the predominant one in adults, and mainly occurred in bone marrow. Normally, 2.4 
million new erythrycotes per second are produced within bone marrow (BM) from 
erythroid progenitors to enucleated reticulocytes and eventually mature 
erythrocytes with a 120 day life span in the peripheral circulation. Basal 
erythropoiesis can be further induced, known as stress erythropoiesis, in response 
to high altitude, blood loss, infection, BM suppression and anemia to produce more 
circulating reticulocytes and erythrocytes to counteract insufficient tissue 
oxygenation1,2. Failure to stimulate effective erythropoiesis, results in hypoxia 
which can progress to pulmonary edema, stroke, cardiovascular damage, multi-
organ injury and death3-6. Thus, stress-induced erythropoiesis is an important 
adaptive response for survival under hypoxic conditions. Erythropoiesis is an 
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extremely dynamic process finely regulated by cytokines, hormones, growth 
factors, among others at transcriptional and translational levels1,2. Stress-induced 
erythropoiesis  is defined  as astimulated basal erythropoiesis with expansion of 
the erythroid progenitor pool, resulting in reticulocytosis and splenomegaly. Stress 
erythropoiesis is frequently  induced  by  insufficient  tissue  oxygenation  including  
high altitude, blood loss, infection, myeloablation, and anemia. Inability to adapt to 
hypoxia associated with these conditions can result in multi-tissue damage, stroke, 
cardiovascular dysfunction and even death3 6. Thus, stress erythropoiesis is an 
important hypoxic adaptive response for survival. Stress erythropoiesis has been 
long speculated to be linked with increased metabolic requirements7, The energy 
metabolism of major nutrient including glucose, glutamine and fatty acids is 
important for the survival, proliferation and differentiation to adapt to physiological 
and pathological stress conditions. With the development of innovative 
metabolomic profiling and state of art isotopically labelled metabolic flux 
approaches8, glucose and glutamine metabolism are essential for stress 
erythropoiesis7· 9 .  
1.6 Sickle cell disease 
        Sickle cell disease is an inherited genetic blood disorder with high mortality 
and morbidity that results from a single mutation in hemoglobin, the protein that 
carries oxygen in red blood cells throughout our bodies. Although this disease was 
discovered more than a century ago, we still lack effective mechanism-based 
therapies. The mutant hemoglobin causes the red blood cells to acquire an unusual 
sickle shape that hinders movement through blood vessels.  The clumps of sickled 
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cells block blood flow resulting in pain, serious infections, and organ damage. Our 
laboratory has discovered a process that contributes to enhanced red blood cell 
sickling, inflammation and progression of the disease and has identified a 
mechanism-based therapeutic approach to inhibit this process. 
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Chapter 2 Role of adenosine signaling in mature erythrocyte 
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2.1 Introduction 
        High-altitude hypoxia is a challenging condition due to limited O2 supply. The 
ability to adjust to high-altitude hypoxia varies considerably among individuals. 
Failure to adapt to high-altitude hypoxia is associated with poor exercise 
performance, severe headache, dizziness and vomiting. Without intervention, it 
can progress to pulmonary and cerebral edema, stroke, cardiovascular dysfunction 
and death89-91. Current strategies to counteract hypoxia are limited due to a lack of 
fundamental understanding of the molecular mechanisms underlying adaptation to 
hypoxia.   
        The erythrocyte is the most abundant circulating cell type and responsible for 
delivery of O2 to peripheral tissues. To function effectively in O2 uptake, transport 
and delivery, erythrocytes rely on sophisticated regulation of Hb-O2 affinity by 
endogenous allosteric modulators. One of the best known allosteric modulators is 
2,3-bisphosphoglycerate (2,3-BPG), a metabolic byproduct of glycolysis 
synthesized primarily in erythrocytes for the purpose of regulating Hb-O2 affinity87. 
It has been known for more than four decades that when humans ascend to high 
altitude the concentration of 2,3-BPG in erythrocytes increases significantly and its 
elevation is correlated with an increased capacity of O2 release from hemoglobin88. 
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However, the molecular basis underlying altitude hypoxia mediated induction of 
erythrocyte 2,3-BPG  remains unknown and the functional role of elevated 
erythrocyte 2,3-BPG in high altitude adaptation is unclear.   
        To identify metabolic alterations of erythrocytes in response to hypoxia, we 
conducted nonbiased high throughput metabolomic profiling of erythrocytes from 
humans at sea level and at high altitude.  Our results confirmed early studies that 
erythrocyte 2,3-BPG levels are significantly elevated in response to high altitude, 
but also led us to discover that circulating adenosine levels and activity of soluble 
CD73 (sCD73), a key enzyme to generate extracellular adenosine, were 
significantly enhanced in 21 lowland volunteers within two hours of arrival at 5260 
m and continued to increase with time at this elevation. Significantly, hypoxia-
induced elevated plasma adenosine level is correlated with erythrocyte 2,3-BPG 
and O2 releasing capacity in human subjects.  In vivo genetic mouse studies 
coupled with in vitro both human and mouse studies demonstrated that increased 
extracellular adenosine signaling via erythrocyte specific ADORA2B, led to the 
sequential activation of AMPK and 2,3-BPG mutase, resulting in increased 2,3-
BPG production and enhanced O2 release capacity to peripheral tissues. Thus, our 
findings highlight the importance of this newly identified erythrocyte adenosine 
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signaling pathway via AMPK in human adaptation to high altitude and identify 
several attractive targets to counteract hypoxia in humans.  
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2.2 Materials and Methods 
2.2.1 Human Subjects  
 
        This study was conducted as part of the Altitudeomics project examining the 
integrative physiology of human responses to hypoxia92. In brief, all procedures 
conformed to the Declaration of Helsinki nd were approved by the Universities of 
Colorado and Oregon Institutional Review Boards and the US Department of 
Defense Human Research Protection office. After written informed consent, 
recreationally active sea-level habitants participated in the adenosine study 
(mean±SD age, 21±1 years; stature, 1.78±0.10 m; body mass, 69±11 kg; 
maximum O2 uptake [Vo2max, 6.4±0.2 mL kg1 min1]. The participants were non-
smokers, free from cardiorespiratory disease, born and raised at <1500 m, and had 
not travelled to elevations >1000 m in the 3 months prior to investigation.  
        Each subject was studied near sea level (SL) (130 m, average PB=749 mmHg) 
and on the first and sixteenth days at Mt Chacaltaya, Bolivia (5260 m; average 
PB=406 mmHg; AT1, AT16). Baseline studies at SL were conducted over a two-
week period in Eugene, OR, USA. Approximately one month after the SL studies, 
subjects traveled to Bolivia in pairs on successive days. Upon arrival at El Alto 
(4050m) after an overnight flight, subjects immediately descended to Coroico, 
Bolivia (1525 m; PB=639 mmHg). Subjects rested for 48 hrs in Coroico to limit the 
effects of jet lag and were then driven over three hrs to 5260 m. To provide an 
acute change in inspired PO2 from 1525 m to 5260 m, subjects breathed 
supplemental oxygen (2 L/min, nasal cannula or mask) during the drive. On arrival 
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at 5260 m, the first subject immediately began the experimental protocol as 
previously described92. 
2.2.2 Metabolomic Profiling  
        Metabolomics extraction. RBCs (100 µl) were immediately extracted in ice-
cold lysis/extraction buffer (methanol:acetonitrile:water 5:3:2) at 1:9 dilutions. 
Samples were then agitated at 4°C for 30 min and then centrifuged at 10,000g for 
15min at 4°C. Protein and lipid pellets were discarded, while supernatants were 
stored at -80°C prior to metabolomics analyses93. 
        Metabolomics analysis. Ten µl of RBC extracts were injected into an UHPLC 
system (Ultimate 3000, Thermo, San Jose, CA, USA) and run on a a Kinetex XB-
C18 column (150x2.1 mm i.d., 1.7 µm particle size – Phenomenex, Torrance, CA, 
USA) using a 3min isocratic gradient at 250 µl/min (mobile phase: 5% acetonitrile, 
95% 18 mΩ H2O, 0.1% formic acid). The UHPLC system was coupled online with 
a QExactive system (Thermo, San Jose, CA, USA), scanning in Full MS mode (2 
µscans) at 70,000 resolution in the 60-900 m/z range, 4kV spray voltage, 15 sheath 
gas and 5 auxiliary gas, operated in negative and then positive ion mode (separate 
runs). Calibration was performed before each analysis against positive or negative 
ion mode calibration mixes (Piercenet – Thermo Fisher, Rockford, IL, USA) to 
ensure sub ppm error of the intact mass. Metabolite assignments were performed 
using the software Maven (Princeton, NJ, USA), upon conversion of raw files into 
mzXML format through MassMatrix (Cleveland, OH, USA). The software allows for 
peak picking, feature detection and metabolite assignment against the KEGG 
pathway database. Assignments were further confirmed against chemical formula 
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determination (as gleaned from isotopic patterns and accurate intact mass), and 
retention times against a 619 standard compounds library including nucleosides 
and nucleotide phosphates (SIGMA Aldrich, St. Louis, MO, USA; IROATech, 
Bolton, MA, USA)93. 
        Relative quantitation was performed by exporting integrated peak areas 
values into GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) for 
statistical analysis (One way ANOVA with Tukey multiple column comparison test; 
significance threshold for p-values < 0.01). 
2.2.3 Mouse Subjects 
        Eight to ten-week-old C57BL/6 wild-type (WT) mice were purchased from 
Harlan Laboratories (Indianapolis, IN). Ecto-5'-nucleotidase (CD73)-deficient mice 
and A2B adenosine receptor (ADORA2B)–deficient mice with C57BL/6 
background were generated and genotyped as described before 94. A novel line of 
mice with erythrocyte specific deletion of Adora2b was generated by crossing mice 
homozygous for a floxed Adora2b allele with mice expressing Cre recombinase 
under the control of erythropoietin receptor (EpoR) gene regulatory elements95. All 
protocols involving animal studies were reviewed and approved by the Institutional 
Animal Welfare Committee of the University of Texas Health Science Center at 
Houston. 
2.2.4 Blood collection and preparation 
        Human and mouse blood, respectively, were collected and stored as 
described before 96, 97. Approximately 4 ml human blood was collected with heparin 
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as an anti-coagulant for 2,3-bisphosphoglycerate (2,3-BPG) measurement (Roche) 
as previous 96. A portion of human blood was collected with EDTA as an anti-
coagulant for complete blood count (CBC). For plasma adenosine assay one ml of 
the EDTA collected blood was aliquoted to tubes containing 10 μM dipyridamole 
(an inhibitor of equilibrative nucleoside transporters) and 10 μM deoxycoformycin 
(an inhibitor of adenosine deaminase). Approximately one ml Mouse blood was 
collected similar to human blood as described above98. Human blood was frozen 
at -80℃ after collection and during shipment from the field until assay. 
2.2.5 Measurement of soluble CD73 activity in mouse 
        sCD73 enzyme activity was measured by quantifying the rate of 
ethenoadenosine (E-ADO) as described previously94. In brief, isolated plasma 
were used for sCD73-specific activity measurement. First, 20μl plasma was 
preincubated at room temperature with 200 nM deoxycoformycin (an inhibitor of 
AMP-deaminase) in 0.1 M HEPES (pH 7.4), with 50 μM MgCl, with or without α,β-
methylene ADP (APCP, Sigma-Aldrich, a specific inhibitor of CD73). Then, 
samples were incubated at 37°C for 30 min in the presence of 100 μM E-AMP. 
sCD73 activity was measured by determining E-ADO concentrations with reversed 
phase HPLC as describe before. Absorbance was measured at 260 nm. sCD73 
activity was expressed as the rate of E-ADO produced from E-AMP that is inhibited 
by APCP.  
2.2.6 Measurement of soluble CD73 activity in human 
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        Circulating CD73 enzyme activity in human was measured by quantifying the 
rate of conversion of [3H]-AMP to [3H]-adenosine as described previously99, 100. 
Briefly, sCD73 activity was measured after incubation of plasma with 300 uM 
[3H]AMP (Quotient Bioresearch; GE Healthcare, Rushden, UK) for 60 min at 37°C. 
Mixture then was applied onto Alugram SIL G/UV254 sheets (Macherey-Nagel, 
Germany). Radiolabelled substrates and their products were separated by thin 
layer chromatography (TLC) and quantified by scintillation β-counting. 
2.2.7 Plasma adenosine measurement 
        Plasma adenosine concentration was measured by reversed phase HPLC as 
previously described96, 98. 500 μl plasma was used to isolate adenosine by 
sequentially adding 0.6 M cold perchloric acid, 3 M KHCO3/3.6 N KOH, 1.8 M 
ammonium dihydrogen phosphate (pH 5.1) and phosphoric acid (30%). Next, the 
sample was centrifuged at 20,000 x g for 5 min and the supernatant was transferred 
to a new tube and ready for reversed phase HPLC analysis. Adenosine content 
was normalized to volume and expressed as a concentration. 
2.2.8 Isolation of total erythrocytes and treatment of mouse erythrocytes in 
vitro 
        Blood was collected with heparin as an anti-coagulant, and RBCs were 
isolated by centrifugation at 240 x g for 10 min at room temperature. Packed red 
blood cells (RBCs) were washed 3 times with culture media (F-10 nutrients mix, 
Life Technology) and re-suspended to 4% hematocrit (HCT). One ml of RBCs was 
added to each well of a 12-well plate96. Mouse RBCs were treated with AICAR 
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(TOCRIS, USA) or AICAR (Sigma, USA) at 1mM for 4h under normoxic 
conditions101. At the end of experiments, 2,3-BPG levels were measured, the 
hemoglobin-O2 binding affinity were analyzed and calculated as P50 by Hemox 
analyzer. 
2.2.9 Hypoxyprobe immunohistochemistry in multiple organs with 
quantification 
        Tissue hypoxia levels were assessed by Hypoxyprobe immunohistochemistry 
as described before102, 103. Briefly, animals were administered Hypoxyprobe 
(Hypoxyprobe, Inc.) via intraperitoneal injection (60 mg/kg body weight). One hour 
after injection, tissues including hearts, lungs and kidneys were harvested, fixed 
overnight in 4% buffered formalin, and embedded in paraffin. According to the 
manufacturer’s instructions (Hypoxyprobe-1 Omni-Kit), sections of 4μm were cut 
and mounted on glass slides, deparaffinized through serial baths in xylene and 
rehydrated in a graded series of alcohol and distilled water. Endogenous 
peroxidase activity was quenched by 10 min of incubation in a 3% hydrogen 
peroxide/methanol buffer. Antigen retrieval was enhanced by autoclaving slides in 
sodium citrate buffer (pH 6.0) at 95°C for 15 min. After blocking with a Biotin 
Blocking System (Dako), the slides were then incubated with rabbit anti-
PAb2627AP in a humidified chamber at 4°C overnight. After the primary antibody 
incubation, anti-rabbit IgG ABC staining system kit (VEACTASTAIN ABS-AP, 
VECTOR LAB) was used according to the protocol. Slides were subsequently 
stained with alkaline phosphatase substrate kit (VEACTASTAIN ABS-AP, 
VECTOR LAB) and counterstained with hematoxylin. Quantification of the 
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immunohistochemical staining was performed using the Image-Pro Plus software 
(Media Cybernetics, Bethesda, MD). The density of the red staining was measured. 
The average densities of 20 areas per samples were determined and the SEM is 
indicated. (n=6)  
2.2.10 Immunoprecipitation 
        Erythrocyte pellets were lysed in lysis buffer (1X TBS, 1% NP-40, 5 mM 
EDTA), protease inhibitor cocktail (Sigma-Aldrich, MO), and phosphatase inhibitor 
cocktail (Sigma-Aldrich, MO). The total protein concentration was measured with a 
Protein Assay Kit (Bio-Rad). Cell lysates were precleared with 50 µl Protein A/G 
Sepharose High Performance beads (GE Healthcare Life Sciences), and then 
incubated overnight at 4oC with 50 µl antibody-bound beads prepared according to 
manufacturer’s instructions and rocked gently. After immunoprecipitation, the 
beads were washed 4 times with 1XTBS, and boiled with 2X Laemmli buffer for 
Western blot analysis104. 
2.2.11 Western blot analysis 
        Proteins in human and mice erythrocytes were analyzed by western blotting. 
Frozen erythrocyte pellets were used for protein extraction following the protocol 
as mentioned above. Proteins were run on 5-20% SDS-PAGE gels and transferred 
to nitrocellulose membrane. After blocking (Odyssey Blocking Buffer, LI-COR), 
membranes were incubated with antibody against BPG mutase (Santa Cruz), or 
ADORA2B (Santa Cruz), or p-AMPK substrate (Cell Signaling), or AMPK  and p-
AMPK  (Cell Signaling) respectively as primary antibody. Afterwards, the 
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membranes were probed with secondary antibodies antibody labeled with IRDye 
fluorophores (LI-COR), subsequently scanned and detected by using the 
ODYSSEY imaging system and software (LI-COR)97. 
2.2.12 ELISA measurement of erythrocyte phosphorylation of AMPKα at 
Thr172  
        Erythrocyte protein extraction from human blood were collected as described 
above. Next, phosphorylation levels of erythrocyte AMPKα at Thr172 were 
quantitatively measured by using commercially available ELISA kits. (A Solid 
phase sandwich ELISA, Cell Signaling) 
2.2.13 Mouse bone marrow cell culture to induce erythroid progenitor cells 
and flow cytometry  
        Bone marrow cells (BMCs) were collected by flushing femur and tibias with 
PBS from EpoR-Cre+ , Adora2bf/f/EpoR-Cre+ , and Adora2b-/-mice (8 to 10-week-
old), and single-cell suspensions were obtained by passing through a cell strainer 
and 21-gauge needle105. Next, hematopoietic progenitor cells (HPCs) were 
enriched by negative selection using a mouse hematopoietic progenitor cell 
enrichment kit (Easy Sep, StemCell Technologies)106. Briefly, isolated BMCs were 
first incubated with a series of biotin-conjugated lineage antibodies (Abs) including 
CD5, CD11b, CD19, CD45R, Ly-6G/C, and TER119 Abs, subsequently incubated 
with magnetic beads. The differentiated cells expressing those lineage markers 
bounded with magnetic beads were separated from undifferentiated HPCs by 
magnetic bar. Then enriched HPCs lacking those lineage markers were further 
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isolated by centrifugation. Purified HPCs were further seeded in wells (1x105 
cells/ml), and cultured as previously described with modification for erythroid cells 
differentiation106. In brief, cells were cultured in StemSpan™ Serum-Free 
Expansion Medium (BSA, recombinant human insulin, human Transferrin, 2-
Mercaptoethanol, Iscove’s MDM) mixed with 15% FBS, 50 units/ml penicillin, 
50ug/ml streptomycin, soluble erythropoietic factors and 2 units/ml EPO at 37°C in 
a humidified atmosphere. After 2 days, the attached differentiated cells were 
harvested. The percentage of early stage of erythroid progenitor cells were 
determined by flow cytometry using FITC-conjugated CD71 (erythroid precursors 
marker)106, 107. Harvested erythroid progenitor cells were used for quantification of 
adora2b mRNA level by qRT-PCR as below.  
2.2.14 qRT-PCR analysis of Adora2b mRNA in harvested erythroid 
progentitor cells and tissues 
        RNA were extracted from harvested erythroid progenitor cells and mouse 
lungs, then reverse transcription and real time-PCR were performed as previously 
described97, 108. SYBR green was used for analysis of all the genes, and the relative 
RNA levels were quantified as the ∆∆CT method109. Primers: Mouse Adora2b: 
forward; 5’-GCGAGAGGGATCATTGCTG-3’ and reverse; 
5’CAGGAACGGAGTCAATCCAA-3’,Mouse Gapdh: forward; 5’- 
TGACCTCAACTACATGGTCTACA-3’ and reverse; 5’- 
CTTCCCATTCTCGGCCTTG-3’. 
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2.2.15 Statistics 
        All data are expressed as the mean ± SEM. Data were analyzed for statistical 
significance using GraphPad Prism 5 software (GraphPad Software). Two-tailed 
Student’s t tests (paired or unpaired as appropriate) were applied in 2-group 
analysis. Differences between the means of multiple groups were compared by 
one-way analysis of variance, followed by a Turkey’s multiple comparisons test. P 
value of less than 0.05 was considered significant. The relationship between two 
variables X and Y were analyzed by Pearson product-moment correlation 
coefficient method. P<0.05 (two-sided) was considered statistically significant. The 
linear correlation (dependence) is described as R square. 
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2.3 Results 
2.3.1 Metabolomic screening reveals that altitude hypoxia activates the 
Rapoport-Luebering Shunt in erythrocytes resulting in increased production 
of 2,3-BPG and increased oxygen release from hemoglobin 
        To identify metabolic alterations in erythrocyte in response to hypoxia, we 
conducted nonbiased high throughput metabolomic profiling of erythrocytes from 
humans at sea level and at high altitude.  Specifically, we recruited 21 young 
healthy lowland volunteers who were examined at sea level and within two hours 
of arrival at an altitude of approximately 5260 meters (ALT1) and on day 16 at high 
altitude (ALT16) (Fig. 3). Overall, 233 metabolites were confidently identified and 
relatively quantified out of over 9000 detected features (mass to charge ratios) in 
the erythrocytes under sea level conditions and at high altitude (Table 2). Analysis 
of these metabolic changes revealed that the erythrocyte-specific Rapoport-
Luebering shunt, occurring at a branch point in the pathway of anaerobic glycolysis 
for production of 2,3-BPG from 1,3-bisphoglycerate  (1,3-BPG) (Fig. 4A), was 
rapidly activated by high-altitude hypoxia. Specifically, levels of 2,3-BPG and its 
upstream glycolytic intermediate, glyceraldehyde-3-phosphate (G3P), were 
increased within  2 hr of arrival at high altitude (ALT1) and were further elevated 
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on day 16 (ALT16). In contrast, the levels of the erythrocyte 
monophosphoglycerates (3-PG and 2-PG) and phospoenolpyruvate (PEP), the 
three immediate downstream products of 2,3-BPG, were significantly reduced on 
day 1 and further reduced on day 16 at high altitude compared to sea level (Fig. 
4B-E). To further validate our metabolomic screening, we accurately quantified 
erythrocyte 2,3-BPG levels in human samples. Consistently, we found that 
erythrocyte 2,3-BPG levels were significantly induced  within two hours  at high 
altitude hypoxia and further elevated on day 16 at high altitude (Fig. 5). Thus, our 
results indicate that in response to high altitude hypoxia the Rapoport-Luebering 
Shunt is activated resulting in a significant portion of G3P being utilized to produce 
2,3-BPG rather than directly metabolized to the glycolytic intermediate, 3-PG (Fig. 
5).   
        Because 2,3-BPG is an allosteric modulator that decreases Hb-O2 binding 
affinity and thereby promotes O2 release87, it is possible that hypoxia-induced 2,3-
BPG production in erythrocytes triggers O2 release. To test this possibility, we 
quantified the O2 release capacity of erythrocytes by accurately measuring P50, 
the partial pressure of O2 required to achieve 50% Hb-O2 saturation, from human 
subjects at high altitude. We found that erythrocyte P50 values were significantly 
elevated in human subjects after prolonged residence at that altitude (ALT16) 
compared to two hours of arrival at 5260 m (ALT1). Finally, the ratio of 
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(ALT16/ALT1) in erythrocyte 2,3-BPG levels upon extended stay at 5260 m was 
significantly correlated with the ratio of (ALT16/ALT1) in erythrocyte P50, reflecting 
reduced Hb-O2 binding affinity and enhanced erythrocyte O2 release capacity. No 
differences were noted between male and female subjects (Fig. 6). These findings 
provide evidence that high altitude hypoxia coordinately induces erythrocyte 2,3-
BPG production and P50 in humans adapting to high altitude (Fig. 4A).  
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Figure.3. Table of human volunteer characteristics including age, height (HT), weight 
(WT), body mass index (BMI), and schema for high altitude human studies. (n=21). 
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Figure.4.  (A) Schematic drawing of erythrocyte-specific Rapoport-Luebering 
shunt occurring at a branch point in the pathway of anaerobic glycolysis for 2,3-
bisphophoglycerate (2,3-BPG) production. (B-E) Metabolomic profiling reveals the 
significant changes in the relative erythrocyte concentration of glyceraldehyde-3-
phosphate (G3P) (B), bisphosphoglycerate (BPG) (C), the 
monophosphoglycerates, 2-phosphoglycerate (2-PG) and 3-phosphoglycerate (3-
PG) (D) and phophoenopyruvate (PEP) ) (E) at sea level (SL) and at high altitude 
on day 1 and day 16. Data are expressed as mean ± SEM; *P<0.05 vs SL; **P<0.05 
vs ALT1. AU (area under the peak) 
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2.3.2 Extracellular adenosine concentrations and soluble CD73 activity 
increase in humans at high altitude and increased adenosine is correlated 
with elevated erythrocyte 2,3-BPG and O2 release capacity 
        Specific factors and signaling pathways involved in 2,3-BPG induction and 
subsequent O2 release from erythrocytes under high altitude has not been 
previously identified. Recent studies show that increased circulating adenosine is 
involved in 2,3-BPG induction in erythrocytes of sickle cell disease (SCD)96. 
However, whether adenosine signaling contributes to erythrocyte 2,3-BPG 
induction and subsequent O2 release underlying high altitude hypoxia adaptation 
remains unknown. To test this hypothesis, we used high performance liquid 
chromatography (HPLC) to measure plasma adenosine levels in the 21 lowland 
volunteers at sea level and following ascent to high altitude. We found that the 
circulating adenosine levels were elevated within two hours of arrival at high 
altitude compared to sea level and were further elevated on ALT16 following an 
extended stay at 5260 m (Fig. 5). No significant differences in elevated plasma 
adenosine levels were observed between males and females (Fig. 6). Ecto-5’-
nucleotidase (CD73) is an ectoenzyme anchored to the cell surface that plays a 
key role in the synthesis of extracellular adenosine from AMP75. Under certain 
circumstances, the ectoenzyme can be cleaved from the cell surface and exist in 
the circulation as a soluble nucleotidase110. Therefore, we further measured 
soluble CD73 (sCD73) activity in normal individuals at sea level and at high altitude. 
Compared to sea level, sCD73 activity was significantly increased in the human 
subjects within two hours following arrival at 5260 m (ALT1) and further increased 
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following an extended stay at high altitude (AT16) (Fig. 5). There was no significant 
difference in elevated sCD73 activity between males and females in response to 
high altitude (Fig. 6).          
        Taken together, these results show that plasma adenosine concentration and 
sCD73 activity increases rapidly in response to high-altitude hypoxia and that the 
induction of plasma adenosine correlates with the induction of erythrocyte 2,3-BPG 
level and O2 releasing capacity.  
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Figure. 5. Erythrocyte 2,3-BPG concentration, P50 level, plasma adenosine concentration 
and soluble CD73 activity (sCD73) were elevated at high altitude hypoxia on ALT1 and 
ALT16 over SL. Data are expressed as mean ± SEM; *P<0.05 vs SL; **P<0.05 vs ALT1.  
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Figure. 6. No significant differences are observed between male and female 
at high altitude hypoxia in elevated erythrocyte 2,3-BPG concentration, 
elevated P50 levels, elevated plasma adenosine concentration, elevated 
soluble CD73 activity, elevated p-AMPK levels and elevated 2,3-BPG mutase 
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activity. (A-F) Erythrocyte 2,3-BPG concentration, P50 level, plasma adenosine 
concentration, soluble CD73 activity, p-AMPK levels, and 2,3-BPG mutase activity 
were significantly elevated both in male and female at high altitude hypoxia, and 
there were no significant differences between male and female. Data are 
expressed as mean ± SEM; *P<0.05 vs SL; **P<0.05 vs ALT1. 
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2.3.3. Soluble CD73 activity is induced under hypoxia and elevated CD73 is 
essential for hypoxia-induced production of plasma adenosine and 
increased erythrocyte 2,3-BPG level and O2 releasing capacity          
        Although extracellular adenosine is well-known to orchestrate a physiological 
response to tissue injury and hypoxia, nothing is known about the functional role 
of plasma adenosine in the normal erythrocyte under hypoxia. Our human studies 
presented above raise an intriguing hypothesis that elevated plasma adenosine is 
dependent on elevated CD73 and that elevated adenosine has a previously 
unrecognized role in high altitude adaption by regulating 2,3-BPG production and 
Hb-O2 binding affinity  in erythrocytes. To test this hypothesis, we exposed WT and 
CD73-deficient mice (Cd73-/-) to hypoxia (10% oxygen, similar to that at 5260 m) 
for one week. Similar to the human high-altitude studies, we found that sCD73 
activity, plasma adenosine levels, erythrocyte 2,3-BPG and P50 were significantly 
increased in WT mice following 1 week of hypoxia compared to normoxia (Fig. 7A-
D). In contrast, hypoxia-mediated increased plasma adenosine, erythrocyte 2,3-
BPG and erythrocyte O2 releasing capacity were significantly impaired in Cd73-/- 
mice (Fig. 7A-D). These results indicate that in mice sCD73 activity is induced by 
hypoxia, as seen in human volunteers at high altitude, and that sCD73 is required 
for hypoxia-induced plasma adenosine production and elevated erythrocyte 2,3-
BPG levels and O2 releasing capacity.  
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Figure. 7 CD73 is essential for hypoxia-induced plasma adenosine, 
erythrocyte 2,3-BPG concentration and P50 levels in mice. Plasma adenosine 
concentration (A), soluble CD73 activity (B), Erythrocyte 2,3-BPG (C), and P50 (D) 
in WT mice and Cd73-/- mice under normoxia or hypoxia (10% O2 1 week). Data 
are expressed as mean ± SEM; *P<0.05 vs WT under normoxia; **P<0.05 vs WT 
under hypoxia (n=10). 
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2.3.4 CD73-mediated elevated extracellular adenosine protects against 
tissue hypoxia in mice          
        To assess the functional importance of CD73-mediated increased plasma 
adenosine in tissue, we measured the tissue hypoxia levels using a hypoxyprobe 
in WT mice and Cd73-/- mice under normoxic conditions and following one week of 
hypoxia as described above. No hypoxia signals were seen in tissue sections of 
Cd73-/- or WT mice under normoxic conditions (Fig. 8A). However, under hypoxic 
conditions, immunohistochemical (IHC) analysis with the hypoxyprobe revealed 
that multiple organs including kidneys, lungs and hearts displayed mild hypoxic 
signal in WT mice (Fig. 8A). In contrast, 7 days at 10% O2 led to severe hypoxia in 
various organs including kidneys, lungs and hearts of Cd73-/- mice (Fig. 8A). Image 
quantification analysis demonstrated that the intensity of hypoxyprobe in the 
kidneys, lungs and hearts was significantly elevated in Cd73-/- mice compared to 
WT mice (Fig. 8B-D). These results show that CD73-mediated elevation of plasma 
adenosine plays a beneficial role to prevent tissue hypoxia in mice. 
        Hypoxia is known to induce lung injury including pulmonary vascular leakage 
and inflammation111. Thus, we collected bronchoalveolar lavage fluid (BALF) of WT 
and Cd73-/- mice for evaluation of pulmonary damage and inflammation. 
Specifically, we quantified cell count, albumin concentration, and interleukin 6 (IL-
6) concentration in BALF of WT and Cd73-/- mice under normoxia and hypoxia. 
Consistent with our tissue hypoxia staining and MPO activity measurements in the 
48 
 
 
 
 
lung, cell count, albumin and IL-6 concentrations in BALF were slightly induced by 
hypoxia in WT mice and their levels were significantly further increased in Cd73-/- 
mice (Fig. 9A-D). Thus, these results show that CD73-mediated elevation of 
plasma adenosine plays a beneficial role in preventing hypoxia-induced lung 
damage and inflammation in mice.  
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Figure. 8. (A-D) Deletion of Cd73-/- results in elevated tissue hypoxia under hypoxia  
 
(10% O2 1 week). Immunohistochemical analysis of tissue hypoxia by hypoxyprobe.  
 
(B-D) Semi-quantification of the hypoxyprobe staining in multiple tissues including 
 
 kidney, lung and heart of WT mice and Cd73-/- mice under normoxia or 10% O2 1 
 
 week hypoxia condition. Data are expressed as mean ± SEM; *P<0.05 vs WT under 
 
 normoxia; **P<0.05 vs WT under hypoxia (n=10; Scale bar=200M) 
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Figure. 9. (A-D) Deletion of Cd73-/- results in elevated tissue inflammation infiltration in 
multiple tissues, as well as pulmonary dysfunction under hypoxia (10% O2 1 week). 
Analysis of tissue damage by Myeloperoxidase activity (B) in kidney, lung and heart. 
Bronchoalveolar lavage fluid (BALF) total cell count (A), BALF albumin concentration 
(C), BALF interleukin 6 concentration (D) in WT mice and Cd73-/- mice. Data are 
expressed as mean ± SEM; *P<0.05 vs WT under normoxia; **P<0.05 vs WT under 
hypoxia (n=10; Scale bar=200m).  
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2.3.5 ADORA2B underlies hypoxia-induced 2,3-BPG production and oxygen 
release capacity in in vitro cultured mouse erythrocytes 
        It is known that increased extracellular adenosine elicits physiological or 
pathological functions by engaging its four adenosine receptors including ADORA1, 
ADORA2A, ADORA2B, and ADORA3112. Each adenosine receptor has a distinct 
cellular or tissue distribution and affinity for adenosine113. To identify which 
adenosine receptor is responsible for hypoxia-induced 2,3-BPG production and O2 
release capacity in erythrocytes, we conducted genetic studies in four adenosine 
receptor-deficient mice. We found that hypoxia significantly induced 2,3-BPG 
production and O2 release capacity in cultured erythrocytes isolated from WT mice, 
Adora1-deficient mice, Adora2a-deficient mice and Adora3-deficient mice. 
However, hypoxia-mediated effects were absent in cultured erythrocytes isolated 
from Adora2b-deficient mice (Fig. 11A-B), indicating that hypoxia-induced 
erythrocyte 2,3-BPG production and O2 release capacity is dependent on 
ADORA2B. 
2.3.6 Genetic deletion of erythrocyte ADORA2B attenuates hypoxia-induced 
2,3-BPG production and oxygen release capacity in vivo  
        To precisely determine the importance of erythrocyte ADORA2B-mediated 
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elevated 2,3-BPG production and O2 release in hypoxia, we generated mice with 
erythrocyte lineage-specific ablation of Adora2b genes by mating mice with floxed 
Adora2b alleles (Adora2bf/f) with mice containing a transgene expressing Cre 
recombinase only in the erythroid lineage (EpoR-Cre+).  First, we validated the 
specificity and efficiency of ablation of Adora2b in erythroid cells by EpoR-Cre 
using bone marrow (BM) cells  isolated from Epo-Cre+, Adora2bf/f/EpoR-Cre+ and 
Adora2b-/- mice. The BM-derived hematopoietic progenitor cells (HPCs) were 
enriched by negative selection, followed by induction to erythroid progenitor cells 
in erythroid-differentiation medium containing erythropoietin (Fig. 10A). After two 
days, we found that over 96% of harvested HPCs isolated and enriched from Epo-
Cre+, Adora2bf/f/EpoR-Cre+ and Adora2b-/- mice were differentiated into CD71+ 
erythroid progenitor cells, which is consistent with a previous publication (Fig. 
10B)106. Moreover, qRT-PCR analysis showed that erythrocyte lineage Adora2b 
mRNA levels of Adora2bf/f/EpoR-Cre+ were reduced to levels similar to that of 
Adora2b-/- mice, whereas pulmonary Adora2b mRNA levels in Adora2bf/f/EpoR-
Cre+ were still similar to control mice (EpoR-Cre+) (Fig. 10C-D). These results 
demonstrated that we had successfully generated mice with erythrocyte lineage 
specific deletion of Adora2b.  
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        To test the functional role of erythrocyte ADORA2B signaling in response to 
hypoxia, we exposed EpoR-Cre mice and Adora2bf/f/EpoR-Cre+ mice to normoxia 
or hypoxia (10% O2) for one week. The levels of plasma adenosine, erythrocyte 
2,3-BPG and P50 were similar in EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice 
under normoxia (Fig. 11C-E). Following one week of hypoxia exposure, plasma 
adenosine concentrations increased to similar levels in EpoR-Cre+ mice and 
Adora2bf/f/EpoR-Cre+ mice (Fig. 11C). However, the hypoxia-induced erythrocyte 
2,3-BPG production and P50 levels observed in the EpoR-Cre+ mice were 
significantly attenuated in Adora2bf/f/EpoR-Cre+ mice (Fig. 11D-E). Thus, our 
studies provide strong genetic evidence that mouse erythrocyte ADORA2B is 
essential for elevated adenosine-mediated induction of erythrocyte 2,3-BPG and 
O2 releasing capacity under hypoxia.  
2.3.7 Erythrocyte ADORA2B is essential to protect against  tissue hypoxia, 
inflammation and lung damage  
        To further determine if erythrocyte ADORA2B signaling is tissue protective 
under hypoxia, we assessed tissue hypoxia by hypoxyprobe in EpoR-Cre+ mice 
and Adora2bf/f/EpoR-Cre+ mice following one week of hypoxia (10% O2). We found 
that hypoxia treatment led to severe tissue hypoxia in various organs including 
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kidneys, lungs and hearts in Adora2bf/f/EpoR-Cre+ mice, while only a mild hypoxia 
signal was present in those tissues of EpoR-Cre+ mice (Fig. 12A). Image 
quantification analysis demonstrated that the intensity of hypoxyprobe signals in 
kidneys, lungs and hearts were significantly elevated in Adora2bf/f/EpoR-Cre+ mice 
compared to EpoR-Cre+ (Fig. 12B-D) following hypoxia challenge. We also 
observed greater elevation of MPO activity in kidney, lung and heart of 
Adora2bf/f/EpoR-Cre+ mice compared to EpoR-Cre+ mice after hypoxia exposure 
(Fig. 13A). Furthermore, greater lung injury reflected by increased cell counts, 
albumin and IL-6 concentrations in  BALF were detected in Adora2bf/f/EpoR-Cre+ 
mice after hypoxia challenge (Fig. 13B-D). These findings demonstrate that 
erythrocyte ADORA2B is essential for tissue protection during hypoxia exposure. 
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Figure. 10. Effective and specific deletion of Adora2b gene in erythrocyte 
lineage. (A) Schema of generation of erythrocyte specific deletion of Adora2b mice 
by cre/loxp system. (B) Schema of mouse bone marrow-derived erythropoietic 
culture. (C) The percentage of harvested erythroid cells labeled with FITC-
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conjugated CD71 in erythroid progenitor cells of EpoR-Cre+, Adora2b-/- and 
Adora2bf/f/EpoR-Cre+ mice. (D-E) Relative Adora2b mRNA levels in erythroid 
progenitor cells and lung of EpoR-Cre+ mice, Adora2b-/- and Adora2bf/f/EpoR-Cre+ 
mice. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice. (n=6) 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
  
 
Figure. 11. (A-D) Erythrocyte ADORA2B activation induces erythrocyte 2,3-BPG 
production and oxygen release capacity to counteract  tissue hypoxia, inflammation 
and lung damage in mice 
(A and B) Hypoxia induces 2,3-BPG production (A) and P50 (B) levels in cultured WT, 
Adora1-/-, Adora2a-/-, Adora3-/- but not Adora2b-/- mouse erythrocytes in a time-dependent 
manner. *P<0.05 for 3 hours hypoxia vs normoxia; **P<0.05 for 6 hours hypoxia vs 3 
hours hypoxia (n=8). (C-E) Erythrocyte ADORA2B contributes to hypoxia-induced 2,3-
BPG production and P50 levels. Plasma adenosine (C), erythrocyte 2,3-BPG (D) and P50 
(E) of EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice under normoxia or hypoxia (10% 
O2 1 week). Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre
+ mice under 
normoxia; **P<0.05 vs EpoR-Cre+ mice under hypoxia (n=10). 
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Figure. 12. Targeted deletion of erythrocyte ADORA2B results in elevated tissue 
hypoxia (10% O2, 1 week). Immunohistochemical analysis of tissue hypoxia by 
hypoxyprobe (A). Semi-quantification of the hypoxyprobe staining in multiple 
tissues including kidney, lung and heart of EpoR-Cre+ and Adora2bf/f/EpoR-Cre+ 
mice under normoxia or 10% O2 1 week hypoxia condition (B-D). *P<0.05 vs EpoR-
Cre+ mice under normoxia condition; **P<0.05 vs EpoR-Cre+ mice under hypoxia 
condition. (n=10; Scale bar=200 M) 
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Figure. 13. Myeloperoxidase activity (A) in kidney, lung and heart. Bronchoalveolar 
lavage fluid (BALF) total cell count (B), BALF albumin concentration (C), BALF 
interleukin 6 concentration (D) in EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice. 
Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia; 
**P<0.05 vs EpoR-Cre+ mice under hypoxia (n=10; Scale bar=200  
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Figure 14. Erythrocyte ADORA2B is essential for hypoxia-induced p-AMPK, 2,3-
BPG mutase activity, 2,3-BPG concentration and P50 levels in vivo. Erythrocyte p-
AMPKα (quantified by ELISA) (A), 2,3-BPG mutase activity (B), 2,3-BPG 
concentration (C) and P50 (D) of EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ mice 
under normoxia or hypoxia (10% O2, 90% N2) for 1 day, 3 days, and 7 days. Data 
are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia; 
**P<0.05 vs EpoR-Cre+ mice under hypoxia for 1 day; #P<0.05 Adora2bf/f/EpoR-
Cre+ mice vs EpoR-Cre+ mice at the same time point (n=10).  
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Figure 15. (E) Representative western blot and relative image quantification 
analysis of p-AMPKα in erythrocytes of EpoR-Cre+ mice and Adora2bf/f/EpoR-Cre+ 
mice under normoxia or hypoxia (10% O2, 90% N2) for 1 week. (F) Representative 
western blot and relative image quantification analysis of p-AMPK phosphorylated 
2,3-BPG mutase levels in the erythrocyte lysates in EpoR-Cre+ mice and 
Adora2bf/f/EpoR-Cre+ mice under normoxia or hypoxia (n=3). Data are expressed 
as mean ± SEM; *P<0.05 vs EpoR-Cre+ mice under normoxia; **P<0.05 vs EpoR-
Cre+ mice under hypoxia. 
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Figure 16. AICAR treatment significantly stimulated hypoxia-induced erythrocyte 
AMPK phosphorylation (A), 2,3-BPG mutase activity (B), 2,3-BPG production (C) 
and P50 levels (D) compared to saline-treated group in Cd73-/- mice and 
Adora2bf/f/EpoR-Cre+ mice under hypoxia (10% O2, 90% N2) for 3 days. Data are 
expressed as mean ± SEM; *P<0.05 for AICAR-treated mice vs saline-treated mice 
(n=8).  
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2.3.8 AMPK functions downstream of erythrocyte ADORA2B in mice and 
underlies hypoxia-induced 2,3-BPG production by phosphorylation and 
activation of 2,3-BPG mutase  
        Erythrocyte 2,3-BPG is synthesized from the glycolytic intermediate 1,3-BPG 
by 2,3-PBG mutase (Fig. 4A). Factors regulating 2,3-BPG production are poorly 
understood. A previous report provided evidence that 2,3-BPG mutase is 
associated with AMPK in erythrocyte lysates and may be a substrate of AMPK114. 
Additional studies showed that ADORA2B signaling activates AMPK in other 
cellular systems115. Like adenosine, AMPK plays a critical role in multiple cellular 
functions especially under conditions of energy depletion and limited O2 
availability116. However, whether AMPK functions downstream of ADORA2B as a 
key enzyme responsible for hypoxia-induced 2,3-BPG production in erythrocytes 
has not been previously studied. To test this possibility, we exposed EpoR-Cre 
mice and Adora2bf/f/EpoR-Cre+ mice to hypoxia (10% oxygen, similar to that found 
at 5260 m) for different time points. We found that erythrocyte AMPK 
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG level and P50 are significantly 
induced in EpoR-Cre mice after 1 day, 3 days and 7 days hypoxia treatment. 
However, hypoxia induced elevation of AMPK phosphorylation, 2,3-BPG 
mutase/synthase activity, 2,3-BPG and P50 are attenuated in Adora2bf/f/EpoR-
Cre+ mice after 1 day, 3 days and 7 days hypoxia treatment (Fig. 14A-D). These 
studies demonstrated that hypoxia is capable of inducing AMPK phosphorylation, 
subsequently activate 2,3-BPG mutase, generate 2,3-BPG and trigger oxygen 
release, and that erythrocyte ADORA2B is essential for this phenomenon in vivo.  
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        Next, we conducted experiments to assess the interaction between 
erythrocyte AMPK and 2,3-BPG mutase and determine whether activated AMPK 
phosphorylates 2,3-BPG mutase in erythrocytes. First, our immunoblots show that 
basal AMPK phosphorylation levels, as judged by phosphorylation at threonine 
172 (T172) of the subunit, in erythrocytes from Adora2bf/f/EpoR-Cre+ mice and 
EpoR-Cre+ mice under normoxia were similar (Fig. 15A-B).  Phosphorylation of 
AMPK at T172 was significantly induced in erythrocytes of EpoR-Cre+ mice 
following 1 week of hypoxia (10% O2). In contrast, phosphorylation of AMPK was 
suppressed in Adora2bf/f/EpoR-Cre+ mice (Fig. 15A-B). Then, using an antibody 
that recognizes phosphorylated AMPK (p-AMPK) substrates we showed that p-
AMPK specifically phosphorylates 2,3-BPG mutase and that under normoxic 
conditions the levels of AMPK-phosphorylated 2,3-BPG mutase were similar in 
Adora2bf/f/EpoR-Cre+ mice and EpoR-Cre+ mice(Fig. 15C-D). Subsequently, we 
found that hypoxia significantly induced p-AMPK-phosphorylated 2,3-BPG mutase 
in erythrocytes of EpoR-Cre+ mice and that this phosphorylation was significantly 
attenuated in Adora2bf/f/EpoR-Cre+ mice (Fig. 15C-D). Thus, we conclude that 
ADORA2B-induced AMPK phosphorylation, followed by p-AMPK-phosphorylated 
2,3-BPG mutase are key steps in the signaling pathway underlying hypoxia-
induced 2,3-BPG production and O2 release from erythrocytes to peripheral tissues 
in mice.  
 
 
 
65 
 
 
 
 
 
Figure 17. In vitro effects of AMPK activation in mouse erythrocytes.  
(A-D) In vitro effects of AMPK activation. AMPK activator AICAR-induced p-AMPK 
(A), 2,3-BPG mutase activity (B), 2,3-BPG concentration (C) and P50 levels (D) in 
cultured erythrocytes isolated from WT mice in a time-dependent manner. While 
Compound C significantly attenuated effects of AICAR treatment. Data are 
expressed as mean ± SEM; *P<0.05 for AICAR-treated group 2-hour vs 1-hour, 
and for AICAR-treated group 2-hour vs DMSO-treated group 2-hour, **P<0.05 for 
AICAR-treated group 4-hour vs 2-hour, and for AICAR treated-group 4-hour vs 
DMSO-treated group 4-hour. #P<0.05 for AICAR plus Compound C vs AICAR at 
the same time point (n=8). 
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 Figure 18. In vivo effects of AMPK activation in mouse erythrocytes.  
(A-D) In vivo effects of AMPK activation in mouse under normoxia. (E-H) AICAR 
treatment (200mg/kg, IP) significantly stimulated erythrocyte p-AMPK (E), 2,3-BPG 
mutase activity (F), 2,3-BPG production (G) and P50 levels (H) in WT mice 
compared to saline-treated WT mice after 2 hours under normoxia. Data are 
expressed as mean ± SEM; *P<0.05 Saline group vs AICAR-treated group (n=8).  
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2.3.9 AMPK activators induce erythrocyte 2,3-BPG mutase activity, 2,3-BPG 
production and O2 release in mouse in vitro and in vivo  
        Our discovery that erythrocyte AMPK is phosphorylated and subsequently 
phosphorylates 2,3-BPG mutase in response to ADORA2B signaling suggests that 
activation of AMPK may be sufficient to induce 2,3-BPG production by activating 
2,3-BPG mutase. To test this possibility, we conducted in vitro studies to determine 
if AMPK activation is sufficient to induce 2,3-BPG production and trigger oxygen 
release in cultured WT mouse erythrocytes. Initially, we found that two independent 
AMPK activators, AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide) 
and AICAR, significantly induce phosphorylation of AMPK and activity of 2,3-BPG 
mutase in a time dependent manner (Fig. 5a-b). Next, we found that both AMPK 
activators significantly increased 2,3-BPG production and O2 releasing capacity  in 
cultured erythrocytes in a time dependent manner (Fig. 4c-d). Thus, in vitro studies 
demonstrated that AMPK activation is sufficient to induce 2,3-BPG production and 
enhanced O2 release in mouse erythrocytes. However, Compound C 
(dorsomorphin), a potent and selective inhibitor of AMPK, significantly attenuated 
AICAR and AICAR mediated induction of AMPK phosphorylation, 2,3-BPG mutase 
activity, 2,3-BPG and O2 releasing capacity in cultured mouse erythrocytes (Fig. 
5a-d). 
        We extended our in vitro studies to further test if AICAR, a FDA approved 
drug, could induce erythrocyte 2,3-BPG and O2 releasing capacity by stimulating 
erythrocyte AMPK phosphorylation and 2,3-BPG mutase activity in WT mouse in 
vivo. Our results (Fig. 5e-h) show that AICAR pretreatment significantly induced 
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erythrocyte AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG level and 
O2 releasing capacity in WT mouse in vivo. 
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Figure 19.  In vivo effects of AICAR and Compound C treatment under 
hypoxia.  
(A-D) AICAR treatment significantly stimulated erythrocyte p-AMPK (A), 2,3-BPG 
mutase activity (B), 2,3-BPG production (C) and P50 levels (D) in WT mice 
compared to saline-treated WT mice under hypoxia (8% O2) in a time-dependent 
manner, while Compound C treatment significantly attenuated erythrocyte p-AMPK 
(A), 2,3-BPG mutase activity (B), 2,3-BPG production (C) and P50 levels (D) in WT 
mice compared to saline-treated WT mice under hypoxia (8% O2). Data are 
expressed as mean ± SEM; *P<0.05 for 6-hour vs basal level, **P<0.05 for 24-hour 
vs 6-hour. #P<0.05 for AICAR-treated group vs saline group, and Compound C-
treated group vs saline group at the same time point (n=8). 
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Figure 20. In vivo effects of AICAR or Compound C treatment on multiple 
tissues in mice under hypoxia. IHC analysis of tissue hypoxia by hypoxyprobe 
in kidney, lung and heart (E) Semi-quantification of the hypoxyprobe staining in 
multiple tissues including kidney, lung and heart of WT mice under 8% hypoxia 
condition for 24h with or without AICAR/Compound C treatment. Data are 
expressed as mean ± SEM; *P<0.05 vs WT mice under normoxia condition; 
**P<0.05 vs WT mice with saline treatment under hypoxia (n=8; Scale bar=200 M) 
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Figure 21. AICAR treatment prevented tissue inflammation infiltration, while 
Compound C treatment aggravated tissue MPO activity in WT mice under 
hypoxia for 24 hours.  
MPO activity in heart (A), kidney (B) and lung (C). AICAR or Compound C-
treated WT mice after 24 hours hypoxia treatment (n=8). Data are expressed as 
mean ± SEM; *P<0.05 vs WT mice under normoxia; **P<0.05 vs WT mice with 
saline treatment under hypoxia. 
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2.3.10 In vivo effects of AMPK agonist in hypoxia adaptation in mouse 
        To test whether AICAR could prevent hypoxia-induced multiple tissue 
damage in Cd73-/- and Adora2bf/f/EpoR-Cre+ mice by stimulating erythrocyte 2,3-
BPG production and O2 releasing capacity, we treated these mice with AICAR 
under hypoxia (8% oxygen) for 3 days. Our results (Fig. 16A-D) show that AICAR 
treatment restored erythrocyte 2,3-BPG levels and P50 in both Cd73-/- and 
Adora2bf/f/EpoR-Cre+ mice under hypoxia.  
        To determine the in vivo effect of AMPK agonist in hypoxia adaptation in WT 
mouse, we further extended our in vivo studies to treat WT mouse with AICAR 
under hypoxia (8% oxygen) up to 24 hours. We found that AICAR treatment induce 
greater elevation of erythrocyte 2,3-BPG and O2 releasing capacity by further 
stimulating AMPK phosphorylation and 2,3-BPG mutase activity in WT mouse 
compared to saline group under hypoxia (Fig. 18A-D). Further histological results 
demonstrate that AICAR treatment significantly attenuated multiple tissue hypoxia 
including lungs, kidneys and hearts in WT mouse compared to saline group under 
hypoxia condition (Fig. 20A). Image quantification of hypoxyprobe staining 
demonstrated that hypoxic levels were significantly reduced by AICAR treatment 
in WT mouse (Fig. 20B-D). Next, to further determine the effect of AMPK inhibition 
in erythrocyte hypoxia adaptation, we treat WT mice with Compound C under 
hypoxia condition. In contrast, Compound C treatment reduce hypoxia-induced 
AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and O2 releasing 
capacity in WT mouse erythrocyte, thereby lead to enhanced multiple tissue 
hypoxia including lungs, kidneys and hearts compared to saline group under 
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hypoxia condition (Fig. 20A). Image quantification of hypoxyprobe staining 
demonstrated that hypoxic levels were significantly induced by Compound C 
treatment in WT mouse compared to saline group (Fig. 20B-D). Taken together, 
these studies demonstrate that AICAR can override a genetic block to hypoxia-
induced adenosine production (i.e., CD73 deficiency) or erythrocyte ADORA2B 
signaling (erythrocyte-specific ADORA2B deficiency) to stimulate erythrocyte 2,3-
BPG production and O2 release by the pharmacologic activation of AMPK, and can 
facilitate earlier hypoxia adaptation in WT mouse by rapidly inducing erythrocyte 
AMPK phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and subsequent 
O2 release to peripheral tissues. 
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Figure 22. Erythrocyte p-AMPK and 2,3-BPG mutase activity are induced in 
humans at high altitude 
(A and B) Representative western blot and relative image quantification analysis 
(n=3 per group) of p-AMPK levels quantified by ELISA C) and 2,3-BPG mutase 
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activity (D) at high altitude ALT1 and ALT16 over SL. (E and F) Representative 
western blot and relative image quantification analysis (n=3 per group) of p-AMPK 
phosphorylated 2,3-BPG mutase at SL and high altitude on day 1 and day 16 in 
erythrocyte lysates. Data are expressed as mean ± SEM; *P<0.05 for high altitude 
on day 1 vs SL; **P<0.05 for high altitude on day 16 vs day 1. 
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Figure 23. AMPK activation induces erythrocyte 2,3-BPG mutase activity, 2,3-
BPG production and oxygen release in cultured human erythrocytes 
 (A-D) AMPK activator AICAR-induced phosphorylation of AMPK (A), 2,3-BPG 
mutase activity (B), 2,3-BPG concentration (C) and P50 levels (D) in cultured 
normal human erythrocytes under normoxia in a time-dependent manner. 
Compound C significantly attenuated the effect of AICAR treatment. Data are 
expressed as mean ± SEM; *P<0.05 for AICAR-treated 2-hour group vs 1-hour 
group, and for AICAR-treated 2-hour group vs DMSO-treated 2-hour group, 
**P<0.05 for AICAR-treated 4-hour group vs 2-hour group, and for AICAR-treated 
4-hour group vs DMSO-treated 4-hour group. #P<0.05 for AICAR plus Compound 
C vs AICAR at the same time point (n=8). (E) Working model: CD73 is essential 
for high altitude hypoxia-induced plasma adenosine production. Elevated plasma 
adenosine prevents hypoxia-induced tissue inflammation and damage by 
activating ADORA2B on erythrocytes to induce 2,3-BPG mutase activity, 2,3-BPG 
production, and subsequently increased P50 and increased O2 release to 
peripheral hypoxic tissues. AMPK is a key enzyme that functions downstream of 
ADORA2B to activate 2,3-BPG mutase, promote 2,3-BPG production and O2 
release from erythrocytes. Thus, enhancing the CD73-ADORA2B-AMPK signaling 
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pathway is a promising therapeutic strategy to treat or prevent hypoxia-induced 
tissue damage. 
 
2.3.11 AMPK activation-induced 2,3-BPG and O2 release via stimulating 2,3-
BPG mutase in human erythrocytes, and AMPK phosphorylation as well as 
2,3-BPG mutase activity is significantly induced in humans at high altitude. 
        To determine the physiological function and significance of AMPK activation 
in humans, we conducted a series of in vitro studies using human red blood cells. 
First, AICAR and AICAR treatment directly induced AMPK phosphorylation, 2,3-
BPG mutase activity, 2,3-BPG and subsequent O2 release in cultured normal 
human erythrocytes in a time dependent manner (Fig. 23A-D). To further determine 
loss of function of AMPK activation in elevation of AMPK phosphorylation, 2,3-BPG 
mutase activity, 2,3-BPG production and O2 release, we exposed AICAR and 
AICAR treated human normal RBCs with or without compound C. We found that 
compound C significantly suppressed AICAR and AICAR induced AMPK 
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG levels and O2 release in 
cultured human normal RBCs (Fig. 23A-D).          
        Next, we further investigate whether increased AMPK phosphorylation and 
2,3-BPG mutase activity occurs in human erythrocytes at high altitude. We 
measured erythrocyte AMPK phosphorylation by western blot analysis in human 
subjects at sea level and at high altitude on ALT1 and ALT16. We found that 
erythrocyte p-AMPK levels were increased within two hours at high altitude (ALT1) 
and were further elevated following an extended stay at high altitude (ALT16) (Fig. 
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22A-B). In addition to western blotting we also used ELISAs to quantify erythrocyte 
p-AMPK levels and found that p-AMPK levels were significantly increased on ALT1 
and further elevated on ALT16 (Fig. 22C). No significant differences in elevated p-
AMPK levels were observed between male and female volunteers in response to 
high altitude (Fig. 6D). Additionally, we demonstrated that erythrocyte 2,3-BPG 
mutase activity were induced within two hours at high altitude (ALT1) and were 
further elevated following an extended stay at high altitude (ALT16) (Fig. 22D) 
Finally, we demonstrated that levels of AMPK-phosphorylated 2,3-BPG mutase in 
erythrocytes were significantly increased at ALT1, and further enhanced on ALT16 
(Fig. 22E-F). Altogether, we demonstrated that 1) high altitude induces erythrocyte 
2,3-BPG mutase activity; 2) two independent AMPK agonists induce AMPK 
phosphorylation, 2,3-BPG mutase activity, 2,3-BPG production and subsequent O2 
release in cultured human RBCs; 3) compound c inhibits AMPK activation and 
subsequently suppresses AICAR and AICAR induce AMPK phosphorylation, 2,3-
BPG mutase activity, 2,3-BPG production and O2 release in cultured human RBCs.   
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2.4 Discussion 
        It has been known for more than four decades that when humans ascend to 
high altitudes the affinity of Hb for O2 is decreased to make more O2 available to 
hypoxic peripheral tissues88, 117-119. It was also recognized early on that the reduced 
O2 affinity was due in part to the increase in erythrocyte 2,3-BPG which functioned 
as a negative allosteric regulator of Hb-O2 affinity87, 120, 121. The molecular 
mechanisms accounting for the altitude mediated regulation of erythrocyte 2,3-
BPG concentrations were not understood until we conducted non-biased 
metabolomic screening of erythrocytes from a cohort of 21 human volunteers under 
normoxia and high altitude hypoxia. We report here that Rapoport-Luebering Shunt 
responsible for the production of erythrocyte 2,3-BPG is rapidly induced within two 
hours of arrival at 5260 m and increases further upon prolonged stay at that altitude. 
Additionally, we observed that plasma adenosine concentration and sCD73 activity 
increased along with erythrocyte 2,3-BPG levels and O2 releasing capacity in 
humans at high altitude. Using genetic tools, we demonstrated for the first time that 
CD73-dependent elevation of plasma adenosine signaling via erythrocyte specific 
ADORA2B is a key mechanism for hypoxia adaptation by inducing 2,3-BPG 
production and triggering O2 release to counteract multiple tissue severe hypoxia. 
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Mechanistically, we revealed that AMPK is a key enzyme that functions 
downstream of ADORA2B signaling and contributes to hypoxia-induced 2,3-BPG 
production and subsequent O2 release from erythrocytes in mice and humans. 
Overall, both human and mouse studies reported here provide strong evidence 
that CD73-dependent elevation of plasma adenosine, signaling via ADORA2B on 
erythrocytes, plays a beneficial role in preventing altitude-mediated tissue hypoxia 
by inducing 2,3-BPG production and triggering O2 release in a AMPK-dependent 
manner (Fig. 23E). Thus, our findings reveal novel therapeutic targets to protect 
against tissue hypoxia and provide a strong foundation for future clinical trials.  
        Although extracellular adenosine is known to be induced under hypoxia, no 
prior study has reported that circulating adenosine levels are increased at high 
altitude and a role of elevated adenosine in high altitude adaptation has never been 
recognized prior to our study with young healthy human volunteers. Here we 
discovered for the first time that plasma adenosine levels increased within two 
hours of arrival at high altitude and increased further upon prolonged stay at 5260 
m. Consistent with the altitude-dependent increase in plasma adenosine, we also 
found that sCD73 activity was also significantly induced by high altitude. Moreover, 
we confirmed early studies showing that erythrocyte 2,3-BPG and O2 releasing 
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capacity are significantly elevated in humans at high altitude. The elevated plasma 
adenosine concentrations is proportional to increased erythrocyte 2,3-BPG levels 
and O2 releasing capacity. Although adenosine signaling regulates numerous 
cellular and tissue functions by engaging its membrane receptors113, 122, the 
physiological function of adenosine and ADORA2B signaling in normal 
erythrocytes in response to hypoxia was unknown.  
Similar to humans at high altitude, we found that sCD73 activity, circulating 
adenosine levels, erythrocyte 2,3-BPG levels and O2 releasing capacity were 
significantly elevated in wild type mice maintained for 1 week at 10% O2 (equivalent 
to the oxygen level at 5260 m). However, genetic deletion of CD73 significantly 
reduced hypoxia-induced plasma adenosine, erythrocyte 2,3-BPG levels and O2 
release capacity in the mice. The decreased O2 availability to peripheral tissues 
resulted in multiple severely hypoxic tissues. Consistent with our findings, early 
studies showed that genetic deletion of CD73 leads to vascular leakage and 
increased immune cell infiltration in the lungs under hypoxic condition.48, 75 
However, the functional role of CD73-dependent elevated circulating adenosine in 
the induction of 2,3-BPG levels and O2 release capacity from normal erythrocytes 
to protect hypoxic tissue damage was not recognized prior to our studies. 
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Erythrocyte specific ADORA2B knockouts allowed us to demonstrate for the first 
time that ADORA2B is essential for elevated plasma adenosine induced-2,3-BPG 
production and O2 releasing capacity from erythrocytes. The ablation of erythrocyte 
ADORA2B in mice results in severely hypoxic tissues, similar to CD73-deficient 
mice. Thus, we have identified that elevated plasma adenosine signaling via 
erythrocyte ADORA2B plays an important role in preventing multiple hypoxic 
tissues by inducing erythrocyte 2,3-BPG levels and triggering O2 release to local 
tissues. The discovery of this erythrocytes signaling pathway reveals the 
importance of adenosine signaling in adaptation to high altitude hypoxia.  
        AMPK is a well-known metabolic stress-sensing kinase, which plays an 
essential role in regulating cellular energy metabolism.123, 124 In erythrocytes, 
AMPK plays critical roles in regulating oxidative stress and maintaining the integrity 
and life span of the cell101, 125-127. A previous study used a proteomic approach to 
identify 2,3-BPG-mutase as a potential  AMPK target in erythrocytes 114. However, 
a role for AMPK in 2,3-BPG induction under high altitude or hypoxic conditions in 
normal erythrocytes has not been previously investigated. Our current work 
revealed that AMPK, functioning downstream of ADOARA2B, directly 
phosphorylates and activates 2,3-BPG-mutase resulting in increased production of 
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2,3-BPG, thereby promoting O2 release. Moreover, we demonstrated that two 
independent AMPK activators (AICAR and AICAR) induce phosphorylation and 
activation of 2,3-BPG mutase, 2,3-BPG production and O2 release in cultured WT 
mouse erythrocytes. In contrast, Compound C, a potent and selective inhibitor of 
AMPK, significantly attenuated effects of AICAR and AICAR in cultured WT mouse 
erythrocytes. Because of the importance of AMPK in the induction of 2,3-BPG 
production in erythrocytes, we conducted preclinical studies and found that 
pretreatment with AICAR, a FDA-approved drug that has been used safely to treat 
patients with type 2 diabetes since 1957128, prevented multiple severely hypoxic 
tissues both in CD73-deficient mice and erythrocyte specific ADORA2B-deficient 
mice by inducing erythrocyte 2,3-BPG levels and O2 availability to local tissue. 
Moreover, we demonstrated that AICAR can induce earlier hypoxic adaptation by 
rapidly inducing erythrocyte 2,3-BPG levels, triggering O2 release and thereby 
prevent tissue hypoxia in WT mice. However, loss of function of AMPK by 
Compound C treatment leads to suppression of erythrocyte AMPK phosphorylation, 
2,3-BPG mutase activity, 2,3-BPG level and O2 release capacity, thereby abolish 
effect of erythrocyte hypoxia adaptation resulting severe multiple tissue hypoxia. 
The significance of our mouse finding was further supported by human translational 
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studies showing that both AICAR and AICAR induce phosphorylation of AMPK and 
activation of 2,3-BPG mutase, 2,3-BPG production and O2 release in cultured 
normal human erythrocytes. In contrast, Compound C attenuate AMPK activation-
mediated AMPK phosphorylation, 2,3-BPG mutase activation, 2,3-BPG production 
and O2 release in cultured normal human erythrocytes. Strikingly, AMPK 
phosphorylation, 2,3-BPG mutase activity and levels of p-AMPK-phosphorylated 
2,3-BPG mutase are significantly elevated in the erythrocytes of humans under 
high altitude. Thus, preclinical studies in mice and translational studies with human 
volunteers provide a strong foundation for future clinical trials in humans to test the 
ability of AICAR to increase O2 availability in humans adapting to high altitude or 
other hypoxic challenges. Moreover, future clinical trials to treat or prevent high 
altitude sickness or other disease involving hypoxia-induced tissue damage should 
be facilitated by the safety profile and FDA acceptance of AICAR (Fig. 23E). 
        In conclusion, we have identified a functional role of CD73-dependent 
elevated extracellular adenosine signaling in O2 release from Hb in erythrocytes in 
response to hypoxia. This discovery has revealed a previously unrecognized role 
of adenosine signaling in erythrocyte physiology and provides a novel molecular 
mechanism underlying adaptation to high-altitude hypoxia.  Moreover, our finding 
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that AMPK functioning downstream of ADORA2B in erythrocytes activates 2,3-
BPG mutase, subsequently resulting in increased 2,3-BPG production and 
decreased Hb-O2 binding affinity, has important clinical implications.  Overall, our 
current studies have added significant insight to the molecular mechanisms 
underlying human adaptation to hypoxia and thereby have opened up novel 
therapeutic possibilities for prevention and treatment of hypoxia-related diseases.  
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3 Chapter 3  Role of adenosine signaling in erythroid progenitors 
3.1 Introduction 
        Approximately 1011 new RBCs are produced daily through proliferation and 
differentiation of erythroid progenitors descent from hematopoietic stem cells 
(HSC). This so-called erythropoiesis is a dynamic process finely regulated by 
cytokines, hormones, growth factors, among others at transcriptional and 
translational level129, 130. Stress-induced erythropoiesis is defined as a stimulated 
basal erythropoiesis with expansion of the erythroid progenitor pool, resulting in 
reticulocytesis and splenomegaly, in response to stress conditions including 
anemia, hypoxia or infection.  
        Cell differentiation and proliferation is largely regulated by energy metabolism. 
Although stress erythropoiesis has been long speculated to be linked with 
increased metabolic requirements131, it is only until the recent several years with 
innovative metabolomics profiling and state of art isotopically labelled metabolic 
flux approaches132, the importance of fuel resources including glucose and 
glutamine and their transport are revealed133. However, the molecular basis 
promoting metabolic reprogramming to support erythropoiesis in response to 
stress condition remains largely unknown.  
        Insufficient oxygen availability is one of the major stimulus for stress 
erythropoiesis, inability to adapt to those stress conditions will result in multiple-
tissue damage, stroke, cardiovasucular dysfunction and even death89, 90, 134. 
Previous studies have showed that adenosine signaling, a well-known key 
regulator in response to stress condition, is involved in erythropoiesis135. However, 
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whether adenosine signaling contributes to stress erythropoiesis is unknown. 
        Here, our mouse genetic studies showed that activation of adenosine 
signaling via erythroid ADORA2B promotes the expansion of erythroid progenitors 
both in spleen and bone marrow and in this way contributes to stress erythropoiesis 
in two independent in vivo mouse models including hypoxia and PHZ-induced 
anemia. Follow-up unbiased high-throughput metabolic profiling identified that 
erythroid ADORA2B contributes to an overall hypoxia metabolic reprogramming 
with substantial increased glycolysis, TCA cycle intermediates production in 
erythroid progenitors in mice. Mechanistically, we showed that hypoxia-induced 
factor 1 alpha (HIF-1) functions as downstream of erythroid ADORA2B regulating 
hypoxia metabolic reprogramming by regulation of glucose and glutamine 
metabolism and their transporters, subsequently modulates commitment of an 
HSC to erythroid lineage. Taken together, our studies identify that adenosine 
erythroid ADORA2B is a previously unrecognized purinergic signaling underlying 
stress erythropoiesis by regulation of metabolic reprogramming in erythroid 
progenitors, and likely discover novel therapeutic targets to counteract stress-
induced injury by induction of erythropoiesis. 
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3.2 Methods and material 
3.2.1 Mouse Subjects 
        Eight to ten-week-old C57BL/6 wild-type (WT) mice were purchased from 
Harlan Laboratories (Indianapolis, IN). Ecto-5'-nucleotidase (CD73)-deficient mice 
and A2B adenosine receptor (ADORA2B)–deficient mice with C57BL/6 
background were generated and genotyped as described before94. A novel line of 
mice with erythrocyte specific deletion of Hif-1 was generated by crossing mice 
homozygous for a floxed Hif-1 allele with mice expressing Cre recombinase 
under the control of erythropoietin receptor (EpoR) gene regulatory elements95. All 
protocols involving animal studies were reviewed and approved by the Institutional 
Animal Welfare Committee of the University of Texas Health Science Center at 
Houston. 
3.2.2 Plasma Epo measurement 
        Blood was collected with heparin as an anti-coagulant, and plasma were 
collected by centrifugation at 2000 x g for 20 min at room temperature. Then the 
plasma Epo concentration was measured by using commercial ELISA kits. (R&D 
System, Inc.) 
3.2.3 Flow cytometry 
        For flow cytometry analyses, single cell suspensions were first prepared from 
blood, spleen, or bone marrow. ~5x105 cells were washed with PBS/2%FBS (wash 
buffer), then incubated with 1-2µg/ml indicated antibodies 30mins at 4°C.  Mouse 
antibodies used including CD11b-APCCy7, CD71-PECy7, Gr1-APCCy7, Ter119-
Pacific blue (all from Biolegend). Cells were additionally stained with matching 
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isotype controls. For viability assessments, cells were stained with annexin V-APC 
in conjunction with 7-AAD. Cells were then washed with wash  calcium binding 
buffer. Data was acquired with a Beckman-Coulter Gallios Flow Cytometer and 
analyzed with Kaluza1.5 software as previously136.   
3.2.4 RT-PCR 
        RNA extraction, reverse transcription and real time-PCR were performed as 
previously described97, 108. SYBR green was used for analysis of all the genes, and 
the relative RNA levels were quantified as the ∆∆CT method109. Primers: Mouse 
Adora1: forward; 5’-TGTGCCCGGAAATGTACTGG-3’ and reverse; 5’-
TCTGTGGCCCAATGTTGATAAG-3’, Mouse Adora2a: forward; 5’-
GCCATCCCATTCGCCATCA-3’ and reverse; 5’-
GCAATAGCCAAGAGGCTGAAGA-3’, Mouse Adora2b: forward; 5’-
GCGAGAGGGATCATTGCTG-3’ and reverse; 5’-CAGGAACGGAGTCAATCCAA-
3’, Mouse Adora3: forward; 5’-ATACCAGATGTCGCAATGTGC-3’ and reverse; 5’-
GCAGGCGTAGACAATAGGGTT-3’,Mouse Gapdh: forward; 5’- 
TGACCTCAACTACATGGTCTACA-3’ and reverse; 5’- 
CTTCCCATTCTCGGCCTTG-3’; Mouse HIF-1: forward; 5’-
GAAATGGCCCAGTGAGAAAA-3’ and reverse; 5’-
CTTCCAVGTTGCTGACTTGA-3’. 
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3.2.5 Mouse bone marrow stem cell culture ex-vivo  
        Bone marrow cells (BMCs) from WT mice and Adora2b-/- were collected as 
described in Chapter 2. Cultured cells were harvested at 0, 24h and 48h time points 
and then detected by flow cytometry106, 107.  
 
3.3 Results 
3.3.1 Elevated CD73-mediated plasma adenosine is essential for hypoxia-
induced erythroid commitment and erythropoiesis in mice independent of 
plasma erythropoietin 
        To determine whether adenosine contributes to the hypoxia-induced stress 
erythropoiesis, we exposed wild type mice (WT) and CD73-deficient mice (Cd73-/-) 
to hypoxia (10% O2) up to 72h. We found that the soluble CD73 (sCD73) activity 
and levels of plasma adenosine were induced after hypoxia exposure in WT mice 
in a time-dependent manner (Fig. 24A-B). Moreover, eythropoiesis-related 
parameters including percentage of reticulocyte and spleen size were significantly 
induced in response to hypoxia compared to normoxia in WT mice (Fig. 24D-E). 
However, hypoxia-mediated elevation of sCD73, increased plasma adenosine 
level and induction of erythropoiesis were significantly suppressed in Cd73-/- mice 
compared to WT mice. In contrast, plasma erythropoietin (Epo) levels were no 
significant difference between WT and Cd73-/- mice under normoxia or hypoxia 
condition (Fig. 24A-E). Erythropoiesis was detected by flow cytometry in WT mice 
including increased percentage of splenic CD71+ and Ter119+ erythroid progenitors 
in response to hypoxia compared to normoxia, with a similar trend in bone marrow 
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(Fig. 25A). To further evaluate erythroid lineage differentiation, I assessed the 
Ter119+ cells on the basis of CD71 staining from stage I to stage IV which 
represents undifferentiated cells to differentiated cells (Fig. 25B). Hypoxia-induced 
expansion of erythroid progenitors was induced most in the stage II of erythroid 
progenitors in WT mice, but was suppressed in Cd73-/- mice. In contrast, attenuated 
myeloid lineage (CD71-CD11b+, CD71-Gr1+) was detected in bone marrow in WT 
mice as compared to Cd73-/- mice after hypoxia exposure (Fig. 25C). Thus, here I 
provide genetic evidence that CD73-mediated increased plasma adenosine is 
required for hypoxia-induced erythroid commitment and erythropoeisis 
independent of plasma Epo level. 
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Figure24. Elevated CD73-mediated adenosine induction is essential for 
hypoxia-induced erythropoiesis in mice independent of plasma 
erythropoietin 
(A-C) Soluble CD73 (sCD73) activity and levels of plasma adenosine were induced 
after hypoxia exposure in WT mice, but not in Cd73-/- mice in a time-dependent 
manner. Data are expressed as mean ± SEM; *P<0.05 vs WT under normoxia; 
**P<0.05 vs WT under 48h hypoxia (n=10) (C) No difference of elevated 
erythropoietin (Epo) level was detected between WT and Cd73-/- mice under 
normoxia or hypoxia condition. Splenomegaly (D) and percentage of reticulocyte 
(E) and were significantly induced in response to hypoxia compared to normoxia 
in WT mice, but not in Cd73-/- mice in a time-dependent manner. Data are 
expressed as mean ± SEM; *P<0.05 vs WT under normoxia; **P<0.05 Cd73-/- vs 
WT under hypoxia (n=10). 
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Figure. 25. Elevated CD73-mediated adenosine induction is essential for 
hypoxia-induced erythroid expansion in mice  
 (A) Robust erythropoiesis was detected by flow cytometry in WT mice including 
increased percentage of splenic CD71+ or Ter119+ or CD71+/Ter119+ erythroid 
progenitors in response to hypoxia compared to normoxia. (B) Erythroid lineage 
differentiation, reflected by the assessment of Ter119+ cells on the basis of CD71 
staining from stage I to stage IV. Hypoxia-induced expansion of erythroid 
progenitors was induced the most in the stage II of erythroid progenitors in WT 
mice, but was suppressed in Cd73-/- mice. (n=10). Data are expressed as mean ± 
SEM.  
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3.3.2 Adenosine signaling contributes to stress erythropoiesis via erythroid 
ADORA2B  
        There are four GPCR adenosine receptors including ADORA1, ADORA2A, 
ADORA2B, and ADORA3. To determine which adenosine receptor is primarily 
involved in elevated plasma adenosine-mediated stress erythropoiesis in response 
to hypoxia, we specifically isolated the stage II of CD71+Ter119+ splenic erythroids, 
and subsequently assessed the adenosine receptor expression level by qRT-PCR. 
We found that Adora2b was highly expressed in the CD71+Ter119+ erythroids 
compared to the other three adenosine receptors  and that Adora2b gene 
expression was induced the most in these cells under hypoxia compared to 
normoxia (Fig. 26A) , implicating that ADORA2B is likely the major adenosine 
receptor underlying elevated plasma adenosine-induced erythropoiesis under 
hypoxia. To  test this hypothesis, we exposed EpoR-Cre+  mice  (control)  and 
Adora2bf/fEpoR-Cre+ mice (erythroid specific ablation of Adora2b genes) to 
normoxia or hypoxia  (10% O2) up to 72h. 10% O2 hypoxia induced similar levels 
of plasma adenosine in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice. However, 
hypoxia-induced erythropoiesis featured with increased percentage of reticulocyte 
and splenomegaly were significantly attenuated in Adora2bf/fEpoR-Cre+ mice 
compared to EpoR-Cre+ mice (Fig. 26B-C). In addition, genetic deletion of erythroid 
ADORA2B significantly attenuated hypoxia-induced population of stage II-
CD71+Ter119+ erythroids in Adora2bf/fEpoR-Cre+ mice compared to EpoR-Cre+ 
mice. Similar trend were observed in the bone marrow (Fig. 27A). In contrast, Epo 
levels were elevated to a similar extent in EpoR-Cre+ mice and Adora2bf/fEpoR-
Cre+ mice under hypoxia (Fig. 26D). Furthermore, attenuated myeloid lineage 
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(CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+, Ter119-Gr1+) was detected in bone 
marrow of EpoR-Cre+ mice as compared to Adora2bf/fEpoR-Cre+ mice (Fig. 27B-
E). Thus, I provides genetic evidence that adenosine signaling via erythroid 
ADORA2B contributes to hypoxia-induced erythropoiesis by regulation of erythroid 
commitment of HSCs independent of plasma Epo level.  
3.3.3 ADORA2B is critical for commitment of hematopoietic precursors to 
erythroids by regulation of metabolic reprogramming in response to stress 
condition 
        Metabolic pathways and their regulation has been reported to play an 
essential role in proliferating cells. Therefore, stress erythropoiesis with 
substantially stimulated proliferation and differentiation of erythroid progenitors has 
been speculated to be linked with increased metabolic requirements, and nutrient 
including glucose and glutamine were considered as essential supply for the 
erythroid commitment from hematopoietic stem cells.  
Although we showed that erythroid ADORA2B is the specific receptor underlying 
adenosine-mediated expansion of erythroid progenitors and subsequent 
contribution of erythropoiesis in response to hypoxia, the intracellular mechanism 
is still unclear. Therefore, to explore the mechanism underlying adenosine 
ADORA2B-induced expansion of erythroid cells under stress condition, I 
conducted unbiased high throughput metabolomic screening in 
CD71high/Ter119high progenitors isolated from spleen of EpoR-Cre+ mice and 
Adora2bf/fEpoR-Cre+ mice under normoxia and 72 hour hypoxia. Overall, 233 
metabolites were identified and quantified out of over 9000 detected features 
(mass to charge ratios) in these cells. Analysis of these metabolic changes 
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revealed that glucose metabolism including glycolysis, pentose phosphate 
pathway (PPP), glutamine metabolism and glutathione pathway are the most 
induced in control mice under hypoxia. In contrast, hypoxia induced glycolysis, 
TCA cycle intermedaites and glutaminolysis were significantly suppressed in 
Adora2bf/fEpoR-Cre+ mice. Thus, our metabolomic profiling demonstrated for the 
first time that ADORA2B has a previously unrecognized role in "hypoxic metabolic 
reprogramming" to enhance glucose and glutamine metabolism thus promote 
stress erythropoiesis.  
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Figure. 26. Adenosine signaling via ADORA2B on erythroid progenitors 
contributes to stress erythropoiesis 
(A) Four adenosine receptors including ADORA1, ADORA2A, ADORA2B, and 
ADORA3 Adora2b were assessed in the isolated CD71+Ter119+ splenic erythroids 
under normoxia and 72h hypoxia. (B-C) Hypoxia-induced erythropoiesis featured 
with increased percentage of reticulocyte and splenomegaly in EpoR-Cre+ mice, 
was suppressed in Adora2bf/fEpoR-Cre+ mice. (D) Similar plasma Epo levels in 
EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice under hypoxia. Data are 
expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+  under normoxia; **P<0.05 
EpoR-Cre+ vs Adora2bf/fEpoR-Cre+  under hypoxia (n=10). 
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Figure. 27. Adenosine signaling via ADORA2B on erythroid progenitors 
regulates erythroid commitment under hypoxia 
(A) Genetic deletion of erythroid ADORA2B significantly attenuated hypoxia-
induced population of stage II-CD71+Ter119+ erythroids in Adora2bf/fEpoR-Cre+ 
mice compared  to EpoR-Cre+ mice. (B-E) Enhanced erythroid lineage 
(CD71+CD11b-, CD71+Gr1-, Ter119+CD11b-, Ter119+Gr1-), and attenuated 
myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+, Ter119-Gr1+) were 
detected in EpoR-Cre+ mice as compared to Adora2bf/fEpoR-Cre+ mice after 72h 
hypoxia exposure. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ 
under normoxia; **P<0.05 EpoR-Cre+ vs Adora2bf/fEpoR-Cre+  under hypoxia 
(n=10). 
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3.3.4 Erythroid HIF-1 underlies ADORA2B contributes to hypoxia-induced 
stress erythropoiesis by regulation of erythroid commitment 
        How adenosine erythroid ADOA2B signaling regulates metabolic 
reprogramming, and subsequent control of the commitment of erythroid lineage 
from HSCs is still unknown. Previous study showed that HIF-1 activation 
increases Adora2b gene expression under hypoxia. More recently, multiple studies 
showed that ADORA2B feedback induces Hif-1 gene expression in other 
cellular systems. Further, RNA deep sequencing revealed that glucocorticoid-
induced proliferation of erythroid progenitor cells was largely associated with HIF-
1 activation. Thus, I hypothesize that HIF-1 and ADOAR2B reciprocally 
upregulate each other in erythroid progenitor to promote stress erythropoiesis. To 
test this hypothesis, we conducted RT-PCR to show that Hif-1 mRNA is 
significantly induced in these progenitor cells isolated from EpoR-Cre+ mice under 
hypoxia, but not in Adora2bf//fEpoR-Cre+ mice, indicating that ADORA2B induces 
Hif-1 gene expression under hypoxia in erythroid progenitor cells (Fig. 28A). Next, 
to determine the functional role of HIF-1 in hypoxia-induced erythropoiesis, we 
generated Hif-1f/fEpoR-Cre+ erythroid-specific HIF-1  knockouts by mating Hif-
1 f/f mice with EpoR-Cre+ mice. Intriguingly, we found robust hypoxia-induced 
stress erythropoiesis reflected by increased spleen size and percentage of 
reticulocyte in EpoR-Cre+ mice control mice, was suppressed in Hif-1f/fEpoR-Cre+ 
mice (Fig. 28B-C). Moreover, we found that genetic deletion of erythroid HIF-1 
significantly reduced population II of CD71+Ter119+ proerythroblast progenitors in  
spleen compared  to  EpoR-Cre+ control  mice  after  72  hour  hypoxia  exposure 
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(Fig. 28D). Taken together, this provides genetic and pharmacological evidence 
that ADORA2B-HIF-1 pathway contributes to hypoxia-induced stress 
erythropoiesis. 
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Figure. 28. Erythroid HIF-1 contributes to hypoxia induced stress 
erythropoiesis (A) RT-PCR results showed that Hif-1 mRNA is significantly 
induced in isolated CD71+Ter119+ splenic erythroids in EpoR-Cre+ mice under 
hypoxia, but not in Adora2bf/fEpoR-Cre+ mice. (B-C) Hypoxia-induced stress 
erythropoiesis reflected by increased spleen size and percentage of reticulocyte in 
EpoR-Cre+ mice control mice, but was suppressed in Hif-1f/fEpoR-Cre+ mice. (D) 
Genetic deletion of erythroid HIF-1 significantly reduced population II of 
CD71+Ter119+ proerythroblast progenitors in  spleen compared  to EpoR-Cre+ 
control  mice  after  72  hour  hypoxia  exposure. Data are expressed as mean ± 
SEM; *P<0.05 vs EpoR-Cre+ under normoxia; **P<0.05 EpoR-Cre+ vs Hif-
1f/fEpoR-Cre+ mice under hypoxia (n=10). 
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3.3.5 Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in Adora2bf/fEpoR-Cre+ mice in acute anemia model 
        Acute anemia is a life-threatening phenomenon when HCT levels drop 
dramatically in a short period of time, especially in stress conditions. To assess the 
clinical relevance of impaired stress erythropoiesis in Adora2b-/- mice, we utilized a 
phenylhydrazine (PHZ)-induced hemolytic model, which is a well-accepted stress 
erythropoiesis model. 8-12 week old adult mice were consecutive injected with 
PHZ at day 0, 1 and 3 as previously, and erythropoietic parameters were detected 
at day 5. PHZ-treated EpoR-Cre+ mice showed active erythropoiesis at the day 5 
including recovered HCT levels, increased percentages of CD71+ and Ter119+ 
erythroid progenitors in bone marrow. However, impaired erythropoiesis was 
detected in PHZ-treated Adora2bf/fEpoR-Cre+ mice. In contrast, suppressed 
myeloid lineage reflected by CD11b+ staning was detected in EpoR-Cre+ mice, 
while enhanced levels in Adora2bf/fEpoR-Cre+ mice after PHZ treatment (Fig. 29A-
G). To further evaluate erythroid lineage differentiation, we assessed the Ter119+ 
cells on the basis of CD71 staining from stage I to stage IV. Intriguingly, PHZ-
induced expansion of erythroid progenitors was induced the most in the stage II of 
proerythroblasts in EpoR-Cre+ mice, but was suppressed in Adora2bf/fEpoR-Cre+ 
mice (Fig. 30A). 
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3.3.6 Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice in acute anemia model 
        To further evaluate the impact of HIF-1 in acute anemia-induced stress 
erythropoiesis model, EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice were treated 
with consecutive injection of PHZ at day 0, 1 and 3 as previously, and erythropoietic 
parameters were detected at day 5. PHZ-treated EpoR-Cre+ mice showed an 
active erythropoiesis at the day 5 including recovered their HCT levels, increased 
percentages of CD71+ and Ter119+ erythroid progenitors in bone marrow. However, 
impaired erythropoiesis was detected in PHZ-treated Hif-1f/fEpoR-Cre+ mice. In 
contrast, suppressed percentage of myeloid lineage reflected by CD11b+ was 
detected in EpoR-Cre+ mice, while enhanced levels in Hif-1f/fEpoR-Cre+mice after 
PHZ treatment (Fig. 31A-G). To further evaluate erythroid lineage differentiation, 
we assessed the Ter119+ cells on the basis of CD71 staining from stage I to stage 
IV. Intriguingly, PHZ-induced expansion of erythroid progenitors was induced the 
most in the stage II of proerythroblasts in EpoR-Cre+ mice, but was suppressed in 
Hif-1f/fEpoR-Cre+ mice  (Fig. 32A). 
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Figure. 29. Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cells in Adora2bf/fEpoR-Cre+ mice in acute anemia model 
(A-G) Representative flow cytometry results showed that lower HCT level, 
suppressed percentages of CD71+ and Ter119+ erythroid progenitors, but higher 
CD11b myeloid progenitors in Adora2bf/fEpoR-Cre+ mice as compared to EpoR-
Cre+ mice after phenylhydrazine (PHZ) challenge. Data are expressed as mean ± 
SEM; *P<0.05 vs EpoR-Cre+ after PHZ challenge (n=8). 
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Figure. 30. Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in Adora2bf/fEpoR-Cre+ mice after PHZ challenge 
Erythroid lineage differentiation in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice 
were assessed by flow cytometry by quantifying percentage of Ter119+ cells on the 
basis of CD71 staining from stage I to stage IV after PHZ challenge. Erythroid 
commitment in EpoR-Cre+ mice and Adora2bf/fEpoR-Cre+ mice were assessed by 
flow cytometry by quantifying percentage of erythroid lineage (CD71+CD11b-, 
Ter119+CD11b-,), and myeloid lineage (CD71-CD11b+, Ter119-CD11b+) after PHZ 
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ 
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ 
challenge (n=8). 
 
 
113 
 
 
 
 
 
 
 
114 
 
 
 
 
 
Figure. 31. Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice in acute anemia model 
(A-G) Representative flow cytometry results showed that lower HCT level, 
suppressed percentages of CD71+ and Ter119+ erythroid progenitors, but higher 
CD11b myeloid progenitors in Hif-1f/fEpoR-Cre+ mice as compared to EpoR-Cre+ 
mice after phenylhydrazine (PHZ) challenge. Data are expressed as mean ± SEM; 
*P<0.05 vs EpoR-Cre+ after PHZ challenge (n=8).  
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Figure. 32. Impaired commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in Hif-1f/fEpoR-Cre+ mice after PHZ challenge 
Erythroid lineage differentiation in EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice 
were assessed by flow cytometry by quantifying percentage of Ter119+ cells on the 
basis of CD71 staining from stage I to stage IV after PHZ challenge. Erythroid 
commitment in EpoR-Cre+ mice and Hif-1f/fEpoR-Cre+ mice were assessed by 
flow cytometry by quantifying percentage of erythroid lineage (CD71+CD11b-, 
Ter119+CD11b-,), and myeloid lineage (CD71-CD11b+, Ter119-CD11b+) after PHZ 
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ 
challenge. Data are expressed as mean ± SEM; *P<0.05 vs EpoR-Cre+ after PHZ 
challenge (n=8). 
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Figure. 33. CD73-mediated elevated circulating adenosine is responsible for 
increased stress erythropoiesis in SCD Tg mice  
 (A) Plasma adenosine were induced SCD Tg mice as compared to in WT mice, 
but genetic deletion of CD73 in SCD Tg mice background significantly attenuated 
plasma adenosine. (B-D) Splenomegaly and percentage of reticulocyte were 
significantly increased in SCD Tg mice as compared in WT mice, but genetic 
deletion of CD73 in SCD Tg mice background significantly attenuated increased 
spleen size and reticulocyte percentage. Data are expressed as mean ± SEM; 
*P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD (n=10). 
 
 
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
 
 
 
Figure. 34. Enhanced erythroid lineage versus myeloid lineage in SCD Tg 
mice 
(A-C) Increased erythroid lineage reflected by percentage of splenic CD71+ and 
Ter119+ cells, and decreased myeloid lineage reflected by percentage splenic 
CD11b+ cells were detected by flow cytometry in SCD Tg mice but not in 
SCD/CD73 mice as compared to WT mice. Data are expressed as mean ± SEM; 
*P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD (n=10). 
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Figure. 35. (A-B) Erythroid lineage differentiation, reflected by assess the Ter119+ 
cells on the basis of CD71 staining from stage I to stage IV. Expansion of erythroid 
progenitors was induced the most in the stage II of erythroid progenitors in SCD 
Tg mice, but was suppressed in SCD/CD73 mice as compared to WT mice. Data 
are expressed as mean ± SEM; *P<0.05 vs WT mice; **P<0.05 SCD/CD73 vs SCD 
(n=10). 
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Figure. 36. Increased commitment of erythroid versus myeloid lineage from 
hematopoietic stem cell in SCD Tg mice in a CD73 dependent manner 
(A-D) Erythroid commitment were assessed by flow cytometry by quantifying 
percentage of erythroid lineage (CD71+CD11b-, CD71+Gr1-, Ter119+CD11b-, 
Ter119+Gr1-), and myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119-CD11b+, 
Ter119-Gr1+). Data are expressed as mean ± SEM; *P<0.05 vs WT mice; **P<0.05 
SCD/CD73 vs SCD (n=10). 
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3.3.7 CD73-mediated elevation of plasma adenosine is responsible for stress 
erythropoiesis in humanized sickle cell disease mouse model 
        Sickle cell disease (SCD) is an inherited blood disorder that results from a 
mutation in hemoglobin, the protein that carries O2 in erythrocytes throughout our 
bodies. The mutant hemoglobin causes the erythrocytes to acquire an unusual 
sickle shape that hinders movement through blood vessels. The clumps of sickled 
cells block blood flow resulting in pain, serious infections, and organ damage. It is 
widely accepted that SCD is a type of chronic hypoxia disease model due to the 
abnormal erythrocyte. Previous studies reported that stress erythropoiesis was 
occurred in SCD patients, and our current results showed that activated 
erythropoiesis was observed in SCD transgenic (Tg) mice. However, the molecular 
mechanism involved in activated erythropoiesis in SCD is unclear. Our previous 
studies showed that plasma adenosine is highly induced in both SCD patients and 
SCD Tg mice, and attenuation of circulating adenosine levels by PEG-ADA 
enzyme therapy significantly decreases erythropoietic parameters including spleen 
size and percentage of reticulocyte in SCD Tg mice, indicating that elevated 
plasma adenosine likely contributes to the stress erythropoiesis in SCD Tg mice96. 
To test this hypothesis, we further deletion the CD73, a key enzyme generates 
adenosine extracellularly, in the background of SCD Tg mice. First, our HPLC 
results showed that plasma adenosine level was significantly attenuated in 
SCD/CD73 double knockout mice  (Fig. 33A). Then, we showed that decreased 
plasma adenosine leads to suppressed percentage of reticulocyte and spleen size 
in SCD/CD73 double knockout mice compared to SCD Tg mice (Fig. 33B-D). 
Robust erythropoiesis was detected by flow cytometry in bone marrow reflected by 
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enhanced erythroid lineage including increased CD71+ population, Ter119+ 
population, and CD71+/Ter119+ population. However, activation of erythropoiesis 
was significantly attenuated in SCD/CD73 double knockout mice compared  to 
SCD Tg mice. In addition, genetic deletion of CD73 in SCD Tg mice significantly 
attenuated elevation of stage II-CD71+Ter119+ erythroids compared to SCD Tg 
mice. Similar features were observed in the spleen (Fig. 34A-B and Fig. 35A-C). 
Intriguingly, enhanced myeloid lineage (CD71-CD11b+, CD71-Gr1+, Ter119-
CD11b+, Ter119-Gr1+) was detected in SCD/CD73 double knockout mice as 
compared to SCD mice (Fig. 36A-D). Thus, this provides genetic evidence that 
adenosine signaling contributes to stress erythropoiesis by regulation of erythroid 
commitment of HSCs in SCD Tg mice. 
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Figure 37. Working model of role of adenosine signaling in stress 
erythropoiesis 
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3.4 Discussion  
        Erythropoiesis, the formation of erythrocytes, is a dynamic process finely 
regulated by cytokines, hormones, and growth factors at transcriptional and 
translational levels134, 136. Since erythrocytes, the most abundant cell type in the 
circulation, is the major source of oxygen to local tissues, erythropoiesis is 
stimulated under conditions of insufficient oxygen availability such as high altitude, 
blood loss, infection, and anemia. This so-called stress erythropoiesis process is 
defined by an expansion of the erythroid progenitor pool, associated with 
reticulocytosis and splenomegaly. Thus, stress erythropoiesis is an important 
stress adaptive response for survival. Although stress erythropoiesis has been 
linked with increased metabolic requirements, the molecular basis promoting 
metabolic reprogramming to enhance energy metabolism to support stress 
erythropoiesis remains unclear. Our recent studies identify a decisive role of 
elevated adenosine signaling in stress erythropoiesis. Mouse genetic studies 
showed that activation of adenosine signaling via erythroid ADORA2B promotes 
the commitment of erythroid both in spleen and bone marrow and in this way 
contributes to hypoxia-induced stress erythropoiesis independent of plasma Epo. 
Using unbiased high-throughput metabolic profiling coupled with microarray, we 
identified that erythroid ADORA2B contributes to an overall hypoxia metabolic 
reprogramming with substantially increased glycolysis, TCA cycle intermediates 
are produced by erythroid progenitors in mice. In addition, follow-up mouse anemia 
in vivo and mouse HSC ex-vivo studies showed that erythroid ADORA2B-HIF1 is 
critical for erythroid commitment under stress condition. Thus, our studies identify 
adenosine ADORA2B is a previously unrecognized purinergic signaling underlying 
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hypoxia-induced erythropoiesis by regulation of metabolic reprogramming in 
erythroid progenitors, and likely discover new therapeutic targets to counteract 
hypoxia-induced injury by induction of erythrocyte number. 
        All living cells require energy for survival proliferation and differentiation to 
adapt to physiological and pathological stress conditions by metabolizing three 
major nutrients including glucose, glutamine and fatty acids. Changes in nutrient 
utilization and metabolism is termed "metabolic reprogramming" in response to any 
stimuli137.  
        Although adenosine, HIF-1 is induced by stress conditions such as 
hypoxia138, the role and interaction of these hypoxic sensors in stress 
erythropoiesis were previously unrecognized. By using innovative unbiased high 
throughput metabolomics, coupled with our flux analysis of isotopically labeled 
metabolites, multiple genetic mouse models, we show for the first time that 
elevated adenosine signaling-mediated erythroid ADORA2B-HIF-1 activation 
contributes to stress erythropoiesis. Our studies reported here allow us to identify 
a new pathway of adenosine signaling via erythroid ADORA2B-HIF-1 regulating 
erythroid commitment, and subsequently contributing stress erythropoiesis by 
regulation of metabolic reprogramming. Our findings are novel and significant 
which identify multiple new therapeutic targets to regulate HSC lineage 
commitment, and thereby benefits for normal individuals at stress conditions and 
patients with hematology disorders. 
       Adenosine is ubiquitously existed in almost all of the cell type in our bodies, 
which is critical intermediate metabolite of nucleic acids as a building block. As a 
key signaling molecule, adenosine orchestrates the cellular response to hypoxia, 
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energy depletion, and stress challenge by activation of its G protein-coupled 
receptor (GPCR) on multiple cell types. Our results showed that ablation of 
erythroid ADORA2B in mice results in impaired erythropoiesis in response to stress, 
similar to CD73-deficient mice, indicating that adenosine-activated erythroid 
signaling pathway reveals new dimensions of the importance of adenosine 
signaling in adaptation to stress condition. 
        Although HIF-1 is induced by stress condition, and play an important role in 
regulation of metabolic reprogramming138, the role of HIF-1 in stress 
erythropoiesis is not well characterized. HIF-1 increases Adora2b gene 
expression under stress condition. More recently studies showed that ADORA2B 
feedback induces Hif-1 gene expression in other cellular systems94. By 
generating genetically modified mice with specific knockout in erythroid lineage, 
we showed that adenosine signaling via erythroid ADORA2B coupled with HIF-1 
reciprocal upregulation induces metabolic reprogramming, regulates erythroid 
commitment, and therefore promotes erythropoiesis in response to stress condition.  
        Taken together, our studies reveal novel pathway and molecules linking 
purinergic signaling with erythroid metabolic reprogramming and HIF-1 targeted 
gene expression, which regulate erythroid commitment, and subsequently 
contributing stress erythropoiesis. The significance of our studies could be 
enormous since our results provide new insight to stress erythropoiesis for 
identification of innovative therapeutic approaches to promote erythropoiesis. 
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Chapter 4  
4 Conclusion and future direction 
4.1 Conclusion  
        Hypoxia is a condition in which the whole body or local organ and tissue is 
starved of sufficient oxygen supply. Hypoxia is a particularly dangerous condition 
for both normal individuals under high altitude hypoxia and patients with basic 
cardiovascular, respiratory and hemolytic diseases89, 90. Due to a lack of 
fundamental understanding of the molecular mechanisms underlying adaptation to 
hypoxia, current strategies to counteract hypoxia are limited. As the only cell-type 
responsible for delivering O2 to peripheral tissues in our body, mature RBCs quickly 
respond to hypoxia by increasing its O2 delivery ability. Although it has been long 
speculated that RBC play an important adaptive role in response to hypoxia, 
specific molecules and signaling pathways involved in mature RBC "metabolic 
reprogramming" for rapid response to increase O2 delivery to counteract hypoxia-
induced tissue damage and prevent disease progression remain elusive.   
        By conducting pilot high altitude human studies, we observed that plasma 
adenosine concentration and sCD73 activity increased along with erythrocyte 2,3-
BPG levels and O2 releasing capacity in humans at high altitude. Follow-up mouse 
genetic studies demonstrated for the first time that CD73-dependent elevation of 
plasma adenosine signaling via erythrocyte specific ADORA2B is a key 
mechanism for hypoxia adaptation by inducing 2,3-BPG production and triggering 
O2 release to counteract multiple tissue severe hypoxia. Mechanistically, we 
revealed that AMPK is a key enzyme that functions downstream of ADORA2B 
signaling and contributes to hypoxia-induced 2,3-BPG production and subsequent 
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O2 release from erythrocytes in mice and humans. Overall, both human and mouse 
studies reported here provide strong evidence that CD73-dependent elevation of 
plasma adenosine, signaling via ADORA2B on erythrocytes, plays a beneficial role 
in preventing altitude-mediated tissue hypoxia by inducing 2,3-BPG production and 
triggering O2 release in a AMPK-dependent manner (Fig. 6g). Thus, our findings 
reveal novel therapeutic targets to protect against tissue hypoxia and provide a 
strong foundation for future clinical trials. Our studies here addresses the challenge 
of identifying novel approaches for the safe and effective treatment to counteract 
acute hypoxia, a dangerous condition causing multiple tissue damage, dysfunction 
and sudden death. Our ultimate goal is to transform the results of our innovative 
metabolomic screen to new mechanism-based therapeutics to reduce hypoxia-
induced tissue damage and dysfunction by targeting erythrocyte metabolites and 
their signaling pathways newly identified by our studies. Our research will likely 
provide new insight to our understanding of the molecular mechanisms of 
improving O2 delivery from erythrocytes in any condition facing hypoxia. It may 
reduce morbidity and mortality for the billions individuals worldwide who suffer from 
hypoxia, which is beneficial for the health and well-being of billions of individuals 
with hypoxia. 
        Since it is impossible to analyze tissue damage at different time points in 
humans, we plan to conduct preclinical studies to address these questions in future 
direction. These studies are expected to provide evidence of the therapeutic effects 
of BAY-60-5683 (ADORA2B agonist), AICAR (AMPK agonist) and dipyridamole 
(adenosine booster)  to promote O2 release in human high altitude studies and 
reduce hypoxia. Furthermore, if we validate our mouse studies showing that 
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elevated adenosine-mediated activation of erythrocyte AMPK as we hypothesize, 
enhancing circulating adenosine levels by dipyridamole, ADORA2B by BAY-60-
5683 and activation of AMPK by AICAR may represent novel effective therapeutic 
approaches for the treatment of hypoxia. We expect our human translational 
studies to provide a strong foundation of evidence to move forward quickly to 
conduct clinical trials in humans to prevent and treat hypoxia conditions including 
acute mountain sickness and many diseases associated with hypoxia. 
        Change of O2 release capacity of erythrocytes is not the only adaptive 
mechanism in response to stress condition that contributes to enhancement of O2 
availability. Erythropoiesis, the production of erythrocyte number, is also one of the 
well-known adaptive mechanism in response to stress condition130. Although 
adenosine is well known to be induced by hypoxia, the role and molecular basis of 
adenosine signaling in stress erythropoiesis were not previously recognized. 
Similarly, HIF-1 is known to be induced by hypoxia138. However, the role of HIF-
1 in hypoxia-induced stress erythropoiesis is not well characterized due to lack of 
genetically modified mice with specific knockouts of HIF-1 in erythroid progenitors. 
With proof-of-principle novel genetic tools, our findings that elevated adenosine 
signaling through ADORA2B coupled with HIF-1 reciprocal upregulation to induce 
hypoxic metabolic reprogramming to promote new RBC production to offset 
hypoxia and protect from hypoxic tissue damage. Using multiple innovative 
techniques including high throughput metabolomics analysis and mRNA micro-
array sequencing identify purinergic signaling with erythroid hypoxic metabolic 
reprogramming, coupled with HIF-1 targeted gene expression, contributing to 
erythropoiesis by regulation of erythroid commitment.   
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        Overall, our newly discovered molecular mechanisms underlying purinergic 
signaling with HIF-1 in erythroid metabolic modulation identified by the study here 
will add a new chapter to erythroid physiology and pathology and open up new 
therapeutic possibilities to counter tissue hypoxia at all conditions.  
Thus, our findings that elevated adenosine signaling through erythroid ADORA2B- 
HIF-1 interactively feed forward to induce erythroid progenitor hypoxia metabolic 
reprogramming and stress erythropoiesis is extremely new and novel. Of 
significance, our studies identify new signaling pathway regulating erythroid 
metabolic modulation by a sophisticated and collaborative puringeric signaling 
network linked with HIF-1 to promote erythroid commitment under  stress  
erythropoiesis.   
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4.2 Future direction for chapter 2.   
        Our current studies showed that the activation of ADORA2B signaling is 
essential to stimulate 2,3-BPG production and promote O2 release from RBCs to 
counteract tissue  damage in mice in response to acute hypoxic exposure. 
Recently, our preliminary studies showing for the first time that genetic deletion of 
erythrocyte ADORA2B significantly reduced Ang II-induced RBC 2,3-BPG and P50 
and in turn resulted in more kidney tissue damage featured with proteinuria 
compared to Ang II-infused WT mice. Thus, our study demonstrated the broad 
beneficial role of RBC ADORA2B-mediated elevated 2,3-BPG levels and O2 
delivery Ang II-induced kidney injury model. Additionally, we have recently made 
significant progress showing that AMPK functions downstream of ADORA2B and 
that AMPK activation by AICAR is sufficient to induce 2,3-BPG production and  
enhanced O2 release in cultured human RBCs. These findings immediately 
suggest that promoting ADORA2B and AMPK activation are new therapeutic 
strategies to counteract hypoxia. Therefore, our finding of the beneficial role of 
elevated adenosine signaling via RBC ADOAR2B coupled with AMPK activation to 
promote O2 delivery highlights this signaling pathway as a therapeutic target to 
counteract tissue hypoxia. 
        Because of the importance of adenosine-mediated erythrocyte ADORA2B 
activation in counteracting tissue hypoxia in both hypoxia exposed and Ang II-
infused models, we anticipate that these two drugs will reduce hypoxia or Ang II-
induced tissue damage and dysfunction by rapidly inducing circulating adenosine, 
2,3-BPG and O2 release in these two independent models.  
        The beneficial role of RBC ADORA2B-mediated AMPK signaling in 
136 
 
 
 
 
physiological and pathological hypoxia-induced tissue damage had not been 
recognized until we conducted metabolomic screening and mouse genetic 
studies139. Because hypoxia is frequently associated with CVD, enhancing O2 
release by these two new mechanistic treatments may also improve cardiovascular 
function by reducing tissue damage. Thus, we believe our mechanistic discoveries 
regarding erythrocyte ADOAR2B- mediated AMPK activation and subsequent O2 
release is highly innovative and extremely significant since these findings have 
added a significant new chapter to erythrocyte physiology and open up multiple 
new therapeutic opportunities for the treatment of acute high altitude sickness and 
hypoxia-related diseases. 
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4.3 Future direction for chapter 3. 
        To address what are the key enzymes and gene expression mediated by 
ADORA2B-HIF-1 signaling network contributing to hypoxia metabolic 
reprogramming and supporting stress erythropoiesis, we will take advantage of 
multiple novel mouse genetic tools coupled with several innovative and cutting 
edge metabolic analytical techniques developed by us in recent years as below. 
RNA deep sequencing:  To determine if HIF-1 as a key hypoxic transcription 
factor regulates other genes besides Adora2b, we will use robust RNA deep  
sequencing to compare the overall changes of RNA expression in 
CD71highTer119high progenitors isolated from BM and spleen of EpoR-Cre+,  
Adora2bf/fEpoR-Cre+, HIF-1f/fEpoR-Cre+, mice in response to hypoxia at different 
time points up to 72 hours. We will further use RT-PCR to validate and compare 
the gene expression levels of CD71highTer119high progenitors isolated from BM and 
spleens of EpoR-Cre+, Adora2bf/fEpoR-Cre+, HIF-1f/fEpoR-Cre+ mice under 
normoxia and hypoxia conditions at different time points up to 72 hours with a 
special focus on multiple known HIF-1-targeted genes including Glut1/4, pyruvate 
kinase and pyruvate dehydrogenase kinase.  
        Human in vitro studies: To validate our findings in mouse, after expansion 
human CD34+ BMCs, we will further culture the cells in erythroid differentiation 
medium with or without ADORA2B agonist (BAY-60-5683) or HIF-1 stabilizer 
(DMOG). 
        In addition, we will further validate all of those identified HIF-1-targeted 
genes and metabolic changes from mice in humans by using the treated human 
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CD34+ HSC cultures above. Specifically, we will compare the effects of BAY-60-
5683 or DMOG treatment on AMPK-mediated specific phosphorylation of the 
identified enzymes, gene expression and metabolites in those cells. 
        The proposed studies with multidisciplinary approaches have a high likelihood 
to identify multiple new pathways regulating erythroid metabolic modulation by a 
sophisticated and collaborative puringeric signaling network linked with HIF-1 to 
promote erythroid commitment under stress erythropoiesis, and set up foundation 
to future clinical trials and provide therapeutic strategy to improve effective and 
sufficient erythropoiesis in various conditions. 
       Thus, my dissertation research has identified that adenosine signaling 
functions as novel a molecular mechanism involved in the regulation of erythrocyte 
O2 release capacity and O2 delivery capacity, providing therapeutic possibilities to 
enhance O2 availability and prevent stress-induced tissue damage and 
inflammation. 
 
 
 
 
 
 
 
 
 
139 
 
 
 
 
Bibliography 
 
1. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature. 
2014;509:310-317 
2. Bodin P, Burnstock G. Increased release of atp from endothelial cells during acute 
inflammation. Inflamm Res. 1998;47:351-354 
3. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, Boengler K, 
Schulz R, Robson SC, Colgan SP. Atp release from activated neutrophils occurs via 
connexin 43 and modulates adenosine-dependent endothelial cell function. Circ 
Res. 2006;99:1100-1108 
4. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev 
Immunol. 2011;11:201-212 
5. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-
nucleotidase (cd73). Purinergic Signal. 2006;2:351-360 
6. Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment 
of ischaemic and inflammatory diseases. Nat Rev Drug Discov. 2014;13:852-869 
7. Phatarpekar PV, Wen J, Xia Y. Role of adenosine signaling in penile erection and 
erectile disorders. J Sex Med. 2010;7:3553-3564 
8. Zhang Y, Xia Y. Adenosine signaling in normal and sickle erythrocytes and beyond. 
Microbes Infect. 2012;14:863-873 
9. Karmouty-Quintana H, Xia Y, Blackburn MR. Adenosine signaling during acute and 
chronic disease states. J Mol Med (Berl). 2013;91:173-181 
10. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage 
and repair. Cell Death Differ. 2007;14:1315-1323 
140 
 
 
 
 
11. Eltzschig HK. Extracellular adenosine signaling in molecular medicine. J Mol Med 
(Berl). 2013;91:141-146 
12. Jacobson KA, Balasubramanian R, Deflorian F, Gao ZG. G protein-coupled 
adenosine (p1) and p2y receptors: Ligand design and receptor interactions. 
Purinergic Signal. 2012;8:419-436 
13. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug 
Discov. 2006;5:247-264 
14. Fresco P, Diniz C, Goncalves J. Facilitation of noradrenaline release by activation 
of adenosine a(2a) receptors triggers both phospholipase c and adenylate cyclase 
pathways in rat tail artery. Cardiovasc Res. 2004;63:739-746 
15. Varani K, Gessi S, Dionisotti S, Ongini E, Borea PA. [3h]-sch 58261 labelling of 
functional a2a adenosine receptors in human neutrophil membranes. Br J 
Pharmacol. 1998;123:1723-1731 
16. Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R. Adenosine; 
a physiologic modulator of superoxide anion generation by human neutrophils. 
Adenosine acts via an a2 receptor on human neutrophils. J Immunol. 
1985;135:1366-1371 
17. Li JM, Fenton RA, Cutler BS, Dobson JG, Jr. Adenosine enhances nitric oxide 
production by vascular endothelial cells. Am J Physiol. 1995;269:C519-523 
18. Hein TW, Belardinelli L, Kuo L. Adenosine a(2a) receptors mediate coronary 
microvascular dilation to adenosine: Role of nitric oxide and atp-sensitive 
potassium channels. J Pharmacol Exp Ther. 1999;291:655-664 
19. Wen J, Grenz A, Zhang Y, Dai Y, Kellems RE, Blackburn MR, Eltzschig HK, Xia Y. 
A2b adenosine receptor contributes to penile erection via pi3k/akt signaling 
cascade-mediated enos activation. FASEB J. 2011;25:2823-2830 
141 
 
 
 
 
20. Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A2b adenosine receptor-
mediated induction of il-6 promotes ckd. J Am Soc Nephrol. 2011;22:890-901 
21. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated 
protein kinases. Cell Signal. 2003;15:813-827 
22. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea 
PA. A3 adenosine receptor activation inhibits cell proliferation via 
phosphatidylinositol 3-kinase/akt-dependent inhibition of the extracellular signal-
regulated kinase 1/2 phosphorylation in a375 human melanoma cells. J Biol Chem. 
2005;280:19516-19526 
23. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: Therapeutic 
aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759-
770 
24. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine 
as an agonist at human adenosine receptors expressed in chinese hamster ovary 
cells. Biochem Pharmacol. 2001;61:443-448 
25. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. 
N Engl J Med. 2012;367:2322-2333 
26. Ohta A, Sitkovsky M. Role of g-protein-coupled adenosine receptors in 
downregulation of inflammation and protection from tissue damage. Nature. 
2001;414:916-920 
27. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, 
Thiel M. Physiological control of immune response and inflammatory tissue damage 
by hypoxia-inducible factors and adenosine a2a receptors. Annu Rev Immunol. 
2004;22:657-682 
142 
 
 
 
 
28. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen 
tension: Hif1 alpha and adenosine receptors. Nat Rev Immunol. 2005;5:712-721 
29. Bouma MG, van den Wildenberg FA, Buurman WA. The anti-inflammatory potential 
of adenosine in ischemia-reperfusion injury: Established and putative beneficial 
actions of a retaliatory metabolite. Shock. 1997;8:313-320 
30. Idzko M, Ferrari D, Riegel AK, Eltzschig HK. Extracellular nucleotide and nucleoside 
signaling in vascular and blood disease. Blood. 2014;124:1029-1037 
31. Joyner MJ, Casey DP. Muscle blood flow, hypoxia, and hypoperfusion. J Appl 
Physiol (1985). 2014;116:852-857 
32. Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. 
Nat Med. 2011;17:1391-1401 
33. Leuenberger UA, Gray K, Herr MD. Adenosine contributes to hypoxia-induced 
forearm vasodilation in humans. J Appl Physiol (1985). 1999;87:2218-2224 
34. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2b adenosine 
receptor dampens hypoxia-induced vascular leak. Blood. 2008;111:2024-2035 
35. Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, Ongini E, 
Baker SP, Belardinelli L. A2a-adenosine receptor reserve for coronary vasodilation. 
Circulation. 1998;98:711-718 
36. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, French BA, Linden 
J. Myocardial infarct-sparing effect of adenosine a2a receptor activation is due to 
its action on cd4+ t lymphocytes. Circulation. 2006;114:2056-2064 
37. Koeppen M, Eckle T, Eltzschig HK. Selective deletion of the a1 adenosine receptor 
abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One. 
2009;4:e6784 
143 
 
 
 
 
38. Belardinelli L, Shryock JC, Snowdy S, Zhang Y, Monopoli A, Lozza G, Ongini E, 
Olsson RA, Dennis DM. The a2a adenosine receptor mediates coronary vasodilation. 
J Pharmacol Exp Ther. 1998;284:1066-1073 
39. Blass KE, Forster W, Zehl U. Coronary vasodilation: Interactions between 
prostacyclin and adenosine. Br J Pharmacol. 1980;69:555-559 
40. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and 
their potential as novel drugs. Biochim Biophys Acta. 2011;1808:1290-1308 
41. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, Zhang P, Schnermann J, Bache RJ, 
Chen Y. Adenosine a3 receptor deficiency exerts unanticipated protective effects 
on the pressure-overloaded left ventricle. Circulation. 2008;118:1713-1721 
42. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, 
Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-
nucleotidase (cd73) and a2b adenosine receptors. Circulation. 2007;115:1581-
1590 
43. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A 
protective role for the a1 adenosine receptor in adenosine-dependent pulmonary 
injury. J Clin Invest. 2005;115:35-43 
44. Eckle T, Koeppen M, Eltzschig HK. Role of extracellular adenosine in acute lung 
injury. Physiology (Bethesda). 2009;24:298-306 
45. Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, Colgan SP, Eltzschig HK. 
Signaling through the a2b adenosine receptor dampens endotoxin-induced acute 
lung injury. J Immunol. 2010;184:5271-5279 
46. Eckle T, Grenz A, Laucher S, Eltzschig HK. A2b adenosine receptor signaling 
attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin 
Invest. 2008;118:3301-3315 
144 
 
 
 
 
47. Alencar AK, Pereira SL, Montagnoli TL, Maia RC, Kummerle AE, Landgraf SS, 
Caruso-Neves C, Ferraz EB, Tesch R, Nascimento JH, de Sant'Anna CM, Fraga CA, 
Barreiro EJ, Sudo RT, Zapata-Sudo G. Beneficial effects of a novel agonist of the 
adenosine a2a receptor on monocrotaline-induced pulmonary hypertension in rats. 
Br J Pharmacol. 2013;169:953-962 
48. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, 
Eltzschig HK. Identification of ectonucleotidases cd39 and cd73 in innate protection 
during acute lung injury. J Immunol. 2007;178:8127-8137 
49. Bauerle JD, Grenz A, Kim JH, Lee HT, Eltzschig HK. Adenosine generation and 
signaling during acute kidney injury. J Am Soc Nephrol. 2011;22:14-20 
50. Lee HT, Gallos G, Nasr SH, Emala CW. A1 adenosine receptor activation inhibits 
inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in 
mice. J Am Soc Nephrol. 2004;15:102-111 
51. Joo JD, Kim M, Horst P, Kim J, D'Agati VD, Emala CW, Sr., Lee HT. Acute and 
delayed renal protection against renal ischemia and reperfusion injury with a1 
adenosine receptors. Am J Physiol Renal Physiol. 2007;293:F1847-1857 
52. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and 
adenosine pretreatment: Role of a(1) and a(3) receptors. Am J Physiol Renal 
Physiol. 2000;278:F380-387 
53. Kim M, Chen SW, Park SW, D'Agati VD, Yang J, Lee HT. Kidney-specific 
reconstitution of the a1 adenosine receptor in a1 adenosine receptor knockout 
mice reduces renal ischemia-reperfusion injury. Kidney Int. 2009;75:809-823 
54. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink 
JS, Linden J, Okusa MD. Renal protection from ischemia mediated by a2a 
145 
 
 
 
 
adenosine receptors on bone marrow-derived cells. J Clin Invest. 2003;112:883-
891 
55. Okusa MD, Linden J, Macdonald T, Huang L. Selective a2a adenosine receptor 
activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol. 
1999;277:F404-412 
56. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, 
Eltzschig HK. The reno-vascular a2b adenosine receptor protects the kidney from 
ischemia. PLoS Med. 2008;5:e137 
57. Phillis JW. Adenosine in the control of the cerebral circulation. Cerebrovasc Brain 
Metab Rev. 1989;1:26-54 
58. Chen JF, Lee CF, Chern Y. Adenosine receptor neurobiology: Overview. Int Rev 
Neurobiol. 2014;119:1-49 
59. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and 
brain function. Int Rev Neurobiol. 2005;63:191-270 
60. Gomes CV, Kaster MP, Tome AR, Agostinho PM, Cunha RA. Adenosine receptors 
and brain diseases: Neuroprotection and neurodegeneration. Biochim Biophys Acta. 
2011;1808:1380-1399 
61. Dunwiddie TV, Haas HL. Adenosine increases synaptic facilitation in the in vitro rat 
hippocampus: Evidence for a presynaptic site of action. J Physiol. 1985;369:365-
377 
62. Wei CJ, Li W, Chen JF. Normal and abnormal functions of adenosine receptors in 
the central nervous system revealed by genetic knockout studies. Biochim Biophys 
Acta. 2011;1808:1358-1379 
146 
 
 
 
 
63. Gribkoff VK, Bauman LA. Endogenous adenosine contributes to hypoxic synaptic 
depression in hippocampus from young and aged rats. J Neurophysiol. 
1992;68:620-628 
64. Lloyd HG, Lindstrom K, Fredholm BB. Intracellular formation and release of 
adenosine from rat hippocampal slices evoked by electrical stimulation or energy 
depletion. Neurochem Int. 1993;23:173-185 
65. Latini S, Bordoni F, Corradetti R, Pepeu G, Pedata F. Effect of a2a adenosine 
receptor stimulation and antagonism on synaptic depression induced by in vitro 
ischaemia in rat hippocampal slices. Br J Pharmacol. 1999;128:1035-1044 
66. Calabresi P, Centonze D, Pisani A, Bernardi G. A possible mechanism for the 
aglycemia-induced depression of glutamatergic excitation in the striatum. J Cereb 
Blood Flow Metab. 1997;17:1121-1126 
67. Siesjo BK. Cell damage in the brain: A speculative synthesis. J Cereb Blood Flow 
Metab. 1981;1:155-185 
68. Raichle ME. The pathophysiology of brain ischemia. Ann Neurol. 1983;13:2-10 
69. Kusano Y, Echeverry G, Miekisiak G, Kulik TB, Aronhime SN, Chen JF, Winn HR. 
Role of adenosine a2 receptors in regulation of cerebral blood flow during induced 
hypotension. J Cereb Blood Flow Metab. 2010;30:808-815 
70. Stevens B, Ishibashi T, Chen JF, Fields RD. Adenosine: An activity-dependent 
axonal signal regulating map kinase and proliferation in developing schwann cells. 
Neuron Glia Biol. 2004;1:23-34 
71. Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. Activation of adenosine a3 
receptors reduces ischemic brain injury in rodents. J Neurosci Res. 2006;84:1848-
1855 
147 
 
 
 
 
72. Soricelli A, Postiglione A, Cuocolo A, De Chiara S, Ruocco A, Brunetti A, Salvatore 
M, Ell PJ. Effect of adenosine on cerebral blood flow as evaluated by single-photon 
emission computed tomography in normal subjects and in patients with occlusive 
carotid disease. A comparison with acetazolamide. Stroke. 1995;26:1572-1576 
73. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 
2005;67:1385-1387 
74. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, 
Hansen KR, Thompson LF, Colgan SP. Ecto-5'-nucleotidase (cd73) regulation by 
hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J 
Clin Invest. 2002;110:993-1002 
75. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, 
Colgan SP. Crucial role for ecto-5'-nucleotidase (cd73) in vascular leakage during 
hypoxia. J Exp Med. 2004;200:1395-1405 
76. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN. 
Adenosine promotes wound healing and mediates angiogenesis in response to 
tissue injury via occupancy of a(2a) receptors. Am J Pathol. 2002;160:2009-2018 
77. Hu BH, Zheng XY, McFadden SL, Kopke RD, Henderson D. R-
phenylisopropyladenosine attenuates noise-induced hearing loss in the chinchilla. 
Hear Res. 1997;113:198-206 
78. Hight NG, McFadden SL, Henderson D, Burkard RF, Nicotera T. Noise-induced 
hearing loss in chinchillas pre-treated with glutathione monoethylester and r-pia. 
Hear Res. 2003;179:21-32 
79. Hart ML, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK. Cutting edge: A2b 
adenosine receptor signaling provides potent protection during intestinal 
ischemia/reperfusion injury. J Immunol. 2009;182:3965-3968 
148 
 
 
 
 
80. Eltzschig HK, Rivera-Nieves J, Colgan SP. Targeting the a2b adenosine receptor 
during gastrointestinal ischemia and inflammation. Expert Opin Ther Targets. 
2009;13:1267-1277 
81. Colgan SP, Eltzschig HK. Adenosine and hypoxia-inducible factor signaling in 
intestinal injury and recovery. Annu Rev Physiol. 2012;74:153-175 
82. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK. Hypoxia-
inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion 
injury involves ecto-5'-nucleotidase (cd73) and the a2b adenosine receptor. J 
Immunol. 2011;186:4367-4374 
83. Gnad T, Scheibler S, von Kugelgen I, Scheele C, Kilic A, Glode A, Hoffmann LS, 
Reverte-Salisa L, Horn P, Mutlu S, El-Tayeb A, Kranz M, Deuther-Conrad W, Brust 
P, Lidell ME, Betz MJ, Enerback S, Schrader J, Yegutkin GG, Muller CE, Pfeifer A. 
Adenosine activates brown adipose tissue and recruits beige adipocytes via a2a 
receptors. Nature. 2014;516:395-399 
84. Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Protection from 
ischemic liver injury by activation of a2a adenosine receptors during reperfusion: 
Inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol. 
2004;286:G285-293 
85. Field JJ, Nathan DG, Linden J. Targeting inkt cells for the treatment of sickle cell 
disease. Clin Immunol. 2011;140:177-183 
86. Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto 
F, Neuberg D, Linden J, Nathan DG. Sickle cell vaso-occlusion causes activation of 
inkt cells that is decreased by the adenosine a2a receptor agonist regadenoson. 
Blood. 2013;121:3329-3334 
149 
 
 
 
 
87. Brewer GJ. 2,3-dpg and erythrocyte oxygen affinity. Annu Rev Med. 1974;25:29-
38 
88. Lenfant C, Torrance J, English E, Finch CA, Reynafarje C, Ramos J, Faura J. Effect 
of altitude on oxygen binding by hemoglobin and on organic phosphate levels. J 
Clin Invest. 1968;47:2652-2656 
89. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107-114 
90. Hackett PH, Creagh CE, Grover RF, Honigman B, Houston CS, Reeves JT, Sophocles 
AM, Van Hardenbroek M. High-altitude pulmonary edema in persons without the 
right pulmonary artery. N Engl J Med. 1980;302:1070-1073 
91. Colombo ES, Hoffman I. Acute high-altitude illnesses. N Engl J Med. 
2013;369:1665-1666 
92. Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD. Requirements for 
survivin in terminal differentiation of erythroid cells and maintenance of 
hematopoietic stem and progenitor cells. J Exp Med. 2007;204:1603-1611 
93. D'Alessandro A, Hansen KC, Silliman CC, Moore EE, Kelher M, Banerjee A. 
Metabolomics of as-5 rbc supernatants following routine storage. Vox Sang. 
2015;108:131-140 
94. Zhang W, Zhang Y, Wang W, Dai Y, Ning C, Luo R, Sun K, Glover L, Grenz A, Sun 
H, Tao L, Colgan SP, Blackburn MR, Eltzschig HK, Kellems RE, Xia Y. Elevated ecto-
5'-nucleotidase-mediated increased renal adenosine signaling via a2b adenosine 
receptor contributes to chronic hypertension. Circ Res. 2013;112:1466-1478 
95. Heinrich AC, Pelanda R, Klingmuller U. A mouse model for visualization and 
conditional mutations in the erythroid lineage. Blood. 2004;104:659-666 
96. Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, 
Milburn MV, Carter-Dawson L, Lewis DE, Eltzschig HK, Kellems RE, Blackburn MR, 
150 
 
 
 
 
Juneja HS, Xia Y. Detrimental effects of adenosine signaling in sickle cell disease. 
Nat Med. 2011;17:79-86 
97. Iriyama T, Sun K, Parchim NF, Li J, Zhao C, Song A, Hart LA, Blackwell SC, Sibai 
BM, Chan LL, Chan TS, Hicks MJ, Blackburn MR, Kellems RE, Xia Y. Elevated 
placental adenosine signaling contributes to the pathogenesis of preeclampsia. 
Circulation. 2014 
98. Sun K, Zhang Y, Bogdanov MV, Wu H, Song A, Li J, Dowhan W, Idowu M, Juneja 
HS, Molina JG, Blackburn MR, Kellems RE, Xia Y. Elevated adenosine signaling via 
adenosine a2b receptor induces normal and sickle erythrocyte sphingosine kinase 
1 activity in human and mice. Blood. 2015 
99. Yegutkin GG, Samburski SS, Mortensen SP, Jalkanen S, Gonzalez-Alonso J. 
Intravascular adp and soluble nucleotidases contribute to acute prothrombotic 
state during vigorous exercise in humans. The Journal of physiology. 
2007;579:553-564 
100. Yegutkin GG, Wieringa B, Robson SC, Jalkanen S. Metabolism of circulating adp in 
the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 
and ntpdase1/cd39 activities. FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology. 2012;26:3875-3883 
101. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, 
Schulz E, Munzel T, Lang F. Regulation of erythrocyte survival by amp-activated 
protein kinase. FASEB J. 2009;23:1072-1080 
102. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. Hif-
2alpha, but not hif-1alpha, promotes iron absorption in mice. J Clin Invest. 
2009;119:1159-1166 
151 
 
 
 
 
103. Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, 
Demuth T, Howat WJ, Jodrell DI, Tuveson DA. Gamma secretase inhibition 
promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med. 
2012;209:437-444 
104. Liu C, Wang W, Parchim N, Irani RA, Blackwell SC, Sibai B, Jin J, Kellems RE, Xia 
Y. Tissue transglutaminase contributes to the pathogenesis of preeclampsia and 
stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing 
isopeptide modification. Hypertension. 2014;63:353-361 
105. What is the clinical importance of alterations of the hemoglobin oxygen affinity in 
preserved blood--especially as produced by variations of red cell 2,3 dpg content? 
Vox Sang. 1978;34:111-127 
106. Shuga J, Zhang J, Samson LD, Lodish HF, Griffith LG. In vitro erythropoiesis from 
bone marrow-derived progenitors provides a physiological assay for toxic and 
mutagenic compounds. Proc Natl Acad Sci U S A. 2007;104:8737-8742 
107. Chen K, Liu J, Heck S, Chasis JA, An X, Mohandas N. Resolving the distinct stages 
in erythroid differentiation based on dynamic changes in membrane protein 
expression during erythropoiesis. Proc Natl Acad Sci U S A. 2009;106:17413-17418 
108. Wang W, Parchim NF, Iriyama T, Luo R, Zhao C, Liu C, Irani RA, Zhang W, Ning C, 
Zhang Y, Blackwell SC, Chen L, Tao L, Hicks MJ, Kellems RE, Xia Y. Excess light 
contributes to placental impairment, increased secretion of vasoactive factors, 
hypertension, and proteinuria in preeclampsia. Hypertension. 2014;63:595-606 
109. Xiong Y, Yang P, Proia RL, Hla T. Erythrocyte-derived sphingosine 1-phosphate is 
essential for vascular development. J Clin Invest. 2014;124:4823-4828 
110. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, 
Colgan SP. Coordinated adenine nucleotide phosphohydrolysis and nucleoside 
152 
 
 
 
 
signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine a2b 
receptors. J Exp Med. 2003;198:783-796 
111. Subudhi AW, Bourdillon N, Bucher J, Davis C, Elliott JE, Eutermoster M, Evero O, 
Fan JL, Jameson-Van Houten S, Julian CG, Kark J, Kark S, Kayser B, Kern JP, Kim 
SE, Lathan C, Laurie SS, Lovering AT, Paterson R, Polaner DM, Ryan BJ, Spira JL, 
Tsao JW, Wachsmuth NB, Roach RC. Altitudeomics: The integrative physiology of 
human acclimatization to hypobaric hypoxia and its retention upon reascent. PLoS 
One. 2014;9:e92191 
112. Liu H, Xia Y. Beneficial and detrimental role of adenosine signaling in diseases and 
therapy. J Appl Physiol (1985). 2015;119:1173-1182 
113. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International union of 
pharmacology. Xxv. Nomenclature and classification of adenosine receptors. 
Pharmacol Rev. 2001;53:527-552 
114. Thali RF, Tuerk RD, Scholz R, Yoho-Auchli Y, Brunisholz RA, Neumann D. Novel 
candidate substrates of amp-activated protein kinase identified in red blood cell 
lysates. Biochem Biophys Res Commun. 2010;398:296-301 
115. Peng Z, Borea PA, Varani K, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena 
G, Resta G, Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty 
liver in mice. J Clin Invest. 2009;119:582-594 
116. Nakada D, Saunders TL, Morrison SJ. Lkb1 regulates cell cycle and energy 
metabolism in haematopoietic stem cells. Nature. 2010;468:653-658 
117. Lenfant C, Sullivan K. Adaptation to high altitude. N Engl J Med. 1971;284:1298-
1309 
153 
 
 
 
 
118. Shappell SD, Murray JA, Nasser MG, Wills RE, Torrance JD, Lenfant CJ. Acute 
change in hemoglobin affinity for oxygen during angina pectoris. The New England 
journal of medicine. 1970;282:1219-1224 
119. Lenfant C, Sullivan K. Adaptation to high altitude. The New England journal of 
medicine. 1971;284:1298-1309 
120. Valeri CR, Yarnoz M, Vecchione JJ, Dennis RC, Anastasi J, Valeri DA, Pivacek LE, 
Hechtman HB, Emerson CP, Berger RL. Improved oxygen delivery to the 
myocardium during hypothermia by perfusion with 2,3 dpg-enriched red blood cells. 
Ann Thorac Surg. 1980;30:527-535 
121. Finch CA, Lenfant C. Oxygen transport in man. The New England journal of 
medicine. 1972;286:407-415 
122. Linden J. Molecular approach to adenosine receptors: Receptor-mediated 
mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775-787 
123. Long YC, Zierath JR. Amp-activated protein kinase signaling in metabolic regulation. 
J Clin Invest. 2006;116:1776-1783 
124. Hardie DG, Ross FA, Hawley SA. Ampk: A nutrient and energy sensor that 
maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-262 
125. Wang S, Dale GL, Song P, Viollet B, Zou MH. Ampkalpha1 deletion shortens 
erythrocyte life span in mice: Role of oxidative stress. J Biol Chem. 
2010;285:19976-19985 
126. Foretz M, Hebrard S, Guihard S, Leclerc J, Do Cruzeiro M, Hamard G, Niedergang 
F, Gaudry M, Viollet B. The ampkgamma1 subunit plays an essential role in 
erythrocyte membrane elasticity, and its genetic inactivation induces splenomegaly 
and anemia. FASEB J. 2011;25:337-347 
154 
 
 
 
 
127. Foretz M, Guihard S, Leclerc J, Fauveau V, Couty JP, Andris F, Gaudry M, Andreelli 
F, Vaulont S, Viollet B. Maintenance of red blood cell integrity by amp-activated 
protein kinase alpha1 catalytic subunit. FEBS Lett. 2010;584:3667-3671 
128. Rojas LB, Gomes MB. Metformin: An old but still the best treatment for type 2 
diabetes. Diabetol Metab Syndr. 2013;5:6 
129. Gomes AC, Gomes MS. Hematopoietic niches, erythropoiesis and anemia of chronic 
infection. Exp Hematol. 2016;44:85-91 
130. Zhao JL, Baltimore D. Regulation of stress-induced hematopoiesis. Curr Opin 
Hematol. 2015;22:286-292 
131. Chasis JA, Mohandas N. Erythroblastic islands: Niches for erythropoiesis. Blood. 
2008;112:470-478 
132. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted 
ultrahigh performance liquid chromatography/electrospray ionization tandem mass 
spectrometry platform for the identification and relative quantification of the small-
molecule complement of biological systems. Anal Chem. 2009;81:6656-6667 
133. Weckwerth W. Metabolomics: An integral technique in systems biology. Bioanalysis. 
2010;2:829-836 
134. Maekawa S, Kato T. Diverse of erythropoiesis responding to hypoxia and low 
environmental temperature in vertebrates. Biomed Res Int. 2015;2015:747052 
135. Jing L, Tamplin OJ, Chen MJ, Deng Q, Patterson S, Kim PG, Durand EM, McNeil A, 
Green JM, Matsuura S, Ablain J, Brandt MK, Schlaeger TM, Huttenlocher A, Daley 
GQ, Ravid K, Zon LI. Adenosine signaling promotes hematopoietic stem and 
progenitor cell emergence. J Exp Med. 2015;212:649-663 
136. Couturier J, Hutchison AT, Medina MA, Gingaras C, Urvil P, Yu X, Nguyen C, Mahale 
P, Lin L, Kozinetz CA, Schmitz JE, Kimata JT, Savidge TC, Lewis DE. Hiv replication 
155 
 
 
 
 
in conjunction with granzyme b production by ccr5+ memory cd4 t cells: 
Implications for bystander cell and tissue pathologies. Virology. 2014;462-463:175-
188 
137. Oburoglu L, Romano M, Taylor N, Kinet S. Metabolic regulation of hematopoietic 
stem cell commitment and erythroid differentiation. Curr Opin Hematol. 
2016;23:198-205 
138. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 
2012;148:399-408 
139. Liu H, Zhang Y, Wu H, D'Alessandro A, Yegutkin GG, Song A, Sun K, Li J, Cheng 
NY, Huang A, Edward Wen Y, Weng TT, Luo F, Nemkov T, Sun H, Kellems RE, 
Karmouty-Quintana H, Hansen KC, Zhao B, Subudhi AW, Jameson-Van Houten S, 
Julian CG, Lovering AT, Eltzschig HK, Blackburn MR, Roach RC, Xia Y. Beneficial 
role of erythrocyte adenosine a2b receptor-mediated amp-activated protein kinase 
activation in high-altitude hypoxia. Circulation. 2016;134:405-421 
 
 
 
 
 
 
 
 
 
 
156 
 
 
 
 
VITA 
 
        Hong Liu, the son of Pingsheng Liu and Du Feng, was born in Changsha, 
Hunan, China on October 14th, 1985. After completing his work at high school 
affiliated to Hunan Normal University, Changsha, Hunan, China in 2004, he 
entered the University of South China in Hengyang, Hunan, China, where he 
completed five years training in medical school and got the degree of Bachelor of 
Medicine. In September of 2009 he joined in the graduate school at the Xiangya 
College of Medicine in the Central South University in Changsha, Hunan, China. 
From 2010 to 2011, he worked as a research assistant in the Center for Hearing 
and Deafness at State University of New York at Buffalo, New York, United States. 
In August of 2012 he joined in the The University of Texas  
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences 
to pursue his PhD under supervision of his advisor Dr. Yang Xia.  
 
 
Permanent address:    183 Tongzipo Road, Building 6-307 
                                     Changsha, Hunan 
                                     China 410013 
 
 
 
 
 
